Catalytic Enantioselective Synthesis of Difluorinated Alkyl Bromides

Mark D. Levin[†], John M. Ovian^{†‡}, Jacquelyne A. Read^{†‡}, Matthew S. Sigman^{P*}, and Eric N. Jacobsen^{†*}

[†]Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138, United States

Department of Chemistry, University of Utah, 315 South 1400 East, Salt Lake City, UT 84112, United States

[‡]These authors contributed equally

Experimental Supporting Information

General Considerations	S1
Comments regarding the origins of commercially available starting materials, purification of solvents, and spectroscopic techniques.	
Synthesis of Vinyl Bromide Substrates	S2
Procedures for the preparation of substrates and	
characterization information.	
Synthesis of Chiral Catalysts	S26
Procedure for the preparation of catalysts and characterization	
information. Catalyst structure-activity relationship study.	
Select optimization data and crude reaction mixture NMR spectra.	
General Procedure for Oxidative Rearrangement	S49
General procedure for synthesis, isolation procedures, and	
characterization information for alkyl halides.	
Derivatizations of Products of Oxidative Rearrangement	S82
Procedures for the synthesis, isolation, and characterization of	
derivatives of the secondary alkyl bromides.	
X-ray Crystallography	S91
Details and data for the determination of the absolute configuration.	
References	S97

General Considerations:

General:

All reactions for the preparation of substrates were performed in standard, dry glassware fitted with rubber septa under an inert atmosphere of nitrogen unless otherwise described. All difluorination reactions were performed in low density polyethylene tubes sealed with a low-density polyethylene cap under an atmosphere of air. Reported concentrations refer to solution volumes at room temperature. Concentration of organic solutions under reduced pressure was performed using house vacuum (ca. 40 mm Hg) at 30 °C. Column chromatography was performed with SiliaFlash P60 (230–400 mesh, SiliCycle). Thin layer chromatography (TLC) was used for reaction monitoring and product detection was performed using pre-coated glass plates covered with 0.20 mm silica gel with fluorescent indicator; plates were visualized by exposure to UV light ($\lambda_{ex} = 254$ nm) or by staining with potassium permanganate or ninhydrin.

CAUTION: Pyridine•9HF is a corrosive and toxic substance that will etch glassware. Safe handling can be conducted with plastic syringes and metal needles, with NaHCO₃ (aq.) or NaOH (aq.) employed to quench excess HF. Though


reactions should not be conducted in glassware when employing pyridine•9HF, glassware may be used to quench reactions provided sufficient quantities of base are present. Always handle pyridine•9HF while wearing gloves and in a fumehood. As a precautionary measure, have calcium gluconate gel nearby and apply immediately and liberally on skin exposed to HF.

Materials. Reagents were purchased in reagent grade from commercial suppliers and used as received, unless otherwise described. Anhydrous solvents (dioxane, dichloromethane, N,N-dimethylformamide, and tetrahydrofuran) were prepared by passing the solvent through an activated alumina column.

Instrumentation. Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Varian Mercury-400 or an Inova-500 spectrometer, are reported in parts per million downfield from tetramethylsilane, and are referenced to the residual protium resonances of the NMR solvent (CDCl3: 7.26 [CHCl₃]). Proton-decoupled carbon-13 nuclear magnetic resonance (13C {1 H} NMR) spectra were recorded on an Inova-500 spectrometer, are reported in parts per million downfield from tetramethylsilane, and are referenced to the carbon resonances of the NMR solvent (CDCl₃: 77.3). Chemical shifts for fluorine-19 nuclear magnetic resonance (19F NMR) were recorded on an Inova-500 spectrometer and are reported in parts per million downfield from chlorotrifluoromethane and are referenced to the fluorine resonance of chlorotrifluoromethane ($\delta = 0$). Data are represented as follows: chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sext = sextet, sept = septet, m = multiplet), coupling constants in Hertz (Hz), integration. High resolution mass spectrometric data were obtained on a Thermo q-Exactive Plus coupled with an Ultimate 3000 uHPLC (ESI) or GC (EI). GC analysis was performed using an Agilent 7890A GC system using commercially available columns. Chiral HPLC analysis was performed using an Agilent 1200 series quaternary HPLC system using commercially available CHIRALCEL analytical columns (4.6 x 250 mm).

Synthesis of Vinyl Bromide Substrates and Their Precursors


General Procedure A




The following procedure was adapted from one reported by Legault and coworker.¹ To a 2-dram vial equipped with a septum cap and stir bar was added the propiophenone (1 equiv) and dichloroethane (0.5M). Acetyl bromide (8 equiv) was added all at once via syringe, followed by ZnBr/SiO₂ (1g/mmol substrate) while vigorously stirring. The reaction was allowed to proceed overnight. After this time, the reaction was filtered, washing with DCM, and quenched with NaHCO₃. The solution was then transferred to a separatory funnel, diluted with DCM and additional bicarbonate. The organic layer was separated and the aqueous layer extracted with DCM thrice. The combined organics were then washed with NaHCO₃, H₂O, and brine, and subsequently dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude material was then purified by column chromatography (Hexanes:Et₂O) to afford a mixture of the vinyl bromide and the *gem*-dibromoalkane.

In a vial equipped with a stir bar and septum cap was added the material from the previous step and THF (1M). To the stirred solution was added DBU (1.5 equiv relative to *gem*-dibromoalkane), and the reaction was allowed to proceed overnight. After this time, the mixture was diluted with Et₂O and H₂O. The organic layer was separated and the aqueous layer extracted with Et₂O. The combined organics were then washed with H₂O and brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude material was then purified by column chromatography (Hexanes:Et₂O) to afford the desired product.

General Procedure B




The following procedure was adapted from one reported by Paraja, *et.* $al.^2$ To a vial equipped with a stir var and septum cap was added the boronic acid (1 equiv), Pd₂dba₃ (0.025 equiv), and tri(2-furyl)phosphine (0.15 equiv). The vial was evacuated and backfilled thrice with N₂. To a separate vial equipped with a septum cap was added the *gem*dibromoalkene (1.2 equiv). This was evacuated and backfilled thrice with N₂, followed by addition of dioxane (0.25M in boronic acid). The solution was then sparged with N₂ for 5 minutes. To a third vial equipped with a septum cap was added Cs₂CO₃. This vial was evacuated and backfilled thrice with N₂, followed by addition of H₂O (1M in boronic acid). The solution was then sparged with N₂ for 5 minutes. After this time, the alkene in dioxane and the aqueous Cs₂CO₃ were added simultaneously dropwise to the vial containing the boronic acid. This mixture was allowed to stir vigorously overnight. After this time, the mixture was filtered through celite, washing with EtOAc. The organic layer was then washed with brine thrice, dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude material was then purified by column chromatography (Hexanes:Et₂O) to afford the desired product.




2a, (Z)-1-(1-bromoprop-1-en-1-yl)-3-nitrobenzene. Prepared according to General Procedure A from 3'nitropropiophenone (896 mg, 5 mmol) as a clear, colorless oil, which solidified upon storage (900 mg, 74% yield). ¹H NMR (500 MHz, CDCl₃) δ 8.38 (s, 0H), 8.14 (ddd, J = 8.2, 2.4, 1.0 Hz, 1H), 7.85 (ddd, J = 7.8, 1.9, 1.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 6.45 (q, J = 6.6 Hz, 1H), 2.00 (d, J = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 148.14, 141.61, 133.21, 129.23, 123.72, 122.85, 122.28, 18.30.

HRMS (ESI): for C₉H₉BrNO₂, $[M+H]^+$ calculated m/z = 241.9810 and 243.9791, found m/z = 241.9811 and 243.9790.







2c, (Z)-ethyl 3-(1-bromobut-1-en-1-yl)benzoate. Prepared according to General Procedure B from 3-(ethoxycarbonyl)phenylboronic acid (970 mg, 5 mmol) as a clear, orange oil (396 mg, 28% yield).

¹H NMR (500 MHz, CDCl₃) δ 8.21 – 8.18 (m, 1H), 7.97 (ddd, J = 7.7, 1.7, 1.1 Hz, 1H), 7.73 (ddd, J = 7.8, 2.0, 1.1 Hz, 1H), 7.42 (td, J = 7.8, 0.6 Hz, 1H), 6.29 (t, J = 6.8 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 2.46 – 2.36 (m, 2H), 1.42 (td, J = 7.1, 0.7 Hz, 3H), 1.14 (td, J = 7.6, 0.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 166.17, 140.31, 134.29, 131.87, 130.58, 129.19, 128.38, 128.29, 123.61, 61.14, 26.04, 14.35, 12.80.

HRMS (ESI): for $C_{13}H_{16}BrO_2$, $[M+H]^+$ calculated m/z = 283.0328 and 285.0308, found m/z = 283.0327 and 285.0305.







2d, (Z)-ethyl 3-(1-bromohex-1-en-1-yl)benzoate. Prepared according to General Procedure B from 3-(ethoxycarbonyl)phenylboronic acid (194 mg, 1 mmol) as a clear, yellow oil (155 mg, 49% yield).

¹H NMR (500 MHz, CDCl₃) δ 8.17 (t, J = 1.9 Hz, 1H), 7.95 (dt, J = 7.7, 1.3 Hz, 1H), 7.73 – 7.70 (m, 1H), 7.40 (t, J = 7.8 Hz, 1H), 6.28 (t, J = 6.9 Hz, 1H), 4.40 (q, J = 7.2 Hz, 2H), 2.38 (q, J = 7.2 Hz, 2H), 1.55 – 1.47 (m, 2H), 1.41 (t, J = 7.1 Hz, 5H), 0.95 (t, J = 7.2 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 166.23, 140.41, 133.04, 131.89, 130.57, 129.18, 128.40, 128.30, 124.04, 61.16, 32.31, 30.50, 22.42, 14.35, 13.94.

HRMS (ESI): for $C_{15}H_{20}BrO_2$, $[M+H]^+$ calculated m/z = 311.0641 and 313.0621, found m/z = 311.0640 and 313.0618.






2e, (Z)-1-(1-bromoprop-1-en-1-yl)-3-(trifluoromethyl)benzene. Prepared according to General Procedure A from 3'-(trifluoromethyl)propiophenone (606 mg, 3 mmol) as a clear, colorless oil (580 mg, 73%).


¹H NMR (500 MHz, CDCl₃) δ 7.78 (s, 1H), 7.72 (dt, *J* = 7.8, 1.5 Hz, 1H), 7.58 – 7.53 (m, 1H), 7.49 – 7.44 (m, 1H), 6.38 (q, *J* = 6.6 Hz, 1H), 1.99 (d, *J* = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 140.83, 130.98 (d, *J* = 32.6 Hz), 130.67, 128.76, 128.11, 124.83 (q, *J* = 4.1 Hz), 124.23 (q, *J* = 3.9 Hz), 121.76 (d, *J* = 272.4 Hz), 18.18.

¹⁹F NMR (471 MHz, Chloroform-*d*) δ -65.28.

HRMS (EI): for $C_{10}H_8BrF_3$, $[M]^+$ calculated m/z = 263.9756 and 265.9736, found m/z = 263.9750 and 265.9729.







2f, (Z)-3-(1-bromohex-1-en-1-yl)benzonitrile. Prepared according to General Procedure B from 3-cyanophenylboronic acid (441 mg, 3 mmol) as a clear, orange oil (446 mg, 56% yield).

¹H NMR (600 MHz, CDCl₃) δ 7.80 (s, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.55 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 6.28 (t, J = 6.9 Hz, 1H), 2.38 (q, J = 7.2 Hz, 3H), 1.50 (p, J = 7.5 Hz, 3H), 1.45 – 1.36 (m, 3H), 0.95 (t, J = 7.3 Hz, 5H).

¹³C NMR (126 MHz, CDCl₃) δ 141.24, 134.42, 131.68, 131.49, 129.12, 122.53, 118.45, 112.56, 32.34, 30.38, 22.39, 13.91.

HRMS (ESI): for C₁₃H₁₅BrN, $[M+H]^+$ calculated m/z = 264.0382 and 266.0362, found m/z = 264.0381 and 266.0360.







2g, (Z)-1-bromo-3-(1-bromobut-1-en-1-yl)benzene. Prepared according to General Procedure A from 1-(3-bromophenyl)butan-1-one (227 mg, 1 mmol) as a clear, colorless oil (220 mg, 76%).

¹H NMR (500 MHz, CDCl₃) δ 7.67 (s, 0H), 7.45 (ddd, J = 7.9, 1.8, 1.0 Hz, 1H), 7.41 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.19 (t, J = 7.9 Hz, 1H), 6.22 (t, J = 6.9 Hz, 1H), 2.37 (qd, J = 7.6, 6.9 Hz, 2H), 1.11 (t, J = 7.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 141.97, 134.57, 131.16, 130.46, 129.68, 126.19, 122.96, 122.28, 26.05, 12.83.

HRMS (EI): for C₁₀H₁₀Br₂, [M]⁺ calculated m/z = 287.9144 and 289.9123 and 291.9103, found m/z = 287.9143 and 289.9121 and 291.9102.







2h, (Z)-1-bromo-3-(1-bromo-3-methylbut-1-en-1-yl)benzene. Prepared according to General Procedure A from 1-(3-bromophenyl)-3-methylbutan-1-one (241 mg, 1 mmol) as a clear, colorless oil (240 mg, 79%).

¹H NMR (500 MHz, CDCl₃) δ 7.66 (t, *J* = 1.9 Hz, 1H), 7.43 (dddd, *J* = 22.0, 8.0, 1.9, 1.0 Hz, 2H), 7.19 (t, *J* = 7.9 Hz, 1H), 6.03 (d, *J* = 8.7 Hz, 1H), 2.88 (dp, *J* = 8.8, 6.7 Hz, 1H), 1.10 (d, *J* = 6.7 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 141.99, 139.76, 131.15, 130.49, 129.65, 126.28, 122.25, 121.21, 32.21, 21.68 (d, *J* = 2.1 Hz).

HRMS (EI): for $C_{11}H_{12}Br_2$, $[M]^+$ calculated m/z = 301.9300 and 303.9280 and 305.9259, found m/z = 301.9290 and 303.9268 and 305.9249.







2i, (Z)-1-(1-bromobut-1-en-1-yl)-4-nitrobenzene. Prepared according to General Procedure B from 4-nitrophenylboronic acid (166 mg, 1 mmol) as an orange solid (80 mg, 31% yield).

¹H NMR (500 MHz, CDCl₃) δ 8.20 (d, J = 8.9 Hz, 2H), 7.71 (d, J = 8.9 Hz, 2H), 6.42 (t, J = 6.9 Hz, 1H), 2.51 – 2.36 (m, 2H), 1.16 (t, J = 7.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 147.35, 145.86, 137.16, 128.17, 123.52, 122.36, 26.27, 12.63.

HRMS (ESI): for C₁₀H₁₁BrNO₂, $[M+H]^+$ calculated m/z = 255.9968 and 257.9947, found m/z = 255.9967 and 257.9946.






2j, (Z)-1-(1-bromohex-1-en-1-yl)-4-nitrobenzene. Prepared according to General Procedure B from 4-nitrophenylboronic acid (167 mg, 1 mmol) as an orange oil (140 mg, 50% yield).

¹H NMR (500 MHz, CDCl₃) δ 8.20 – 8.17 (m, 2H), 7.71 – 7.67 (m, 2H), 6.41 (t, *J* = 6.9 Hz, 1H), 2.41 (q, *J* = 7.2 Hz, 2H), 1.55 – 1.49 (m, 2H), 1.42 (h, *J* = 7.2 Hz, 2H), 0.96 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 147.32, 145.95, 135.94, 128.17, 123.52, 122.78, 32.54, 30.33, 22.43, 13.91.

HRMS (EI): for $C_{12}H_{14}BrNO_2$, $[M]^+$ calculated m/z = 283.0202 and 285.0182, found m/z = 283.0200 and 285.0179.





TFO Br CH₃

2k, (Z)-4-(1-bromoprop-1-en-1-yl)phenyl trifluoromethanesulfonate. Prepared according to General Procedure A from 4-propionylphenyl trifluoromethanesulfonate (282 mg, 1 mmol) as a clear, colorless oil (228 mg, 66%). ¹H NMR (500 MHz, CDCl₃) δ 7.61 – 7.56 (m, 2H), 7.25 – 7.21 (m, 2H), 6.32 (q, *J* = 6.6 Hz, 1H), 1.97 (d, *J* = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 149.08, 140.38, 129.20, 128.30, 124.26, 121.09, 118.75 (q, *J* = 320.7 Hz), 18.21. ¹⁹F NMR (471 MHz, CDCl₃) δ -72.79.

HRMS (EI): for $C_{10}H_8BrF_3O_3S$, [M]⁺ calculated m/z = 343.9324 and 345.9304, found m/z = 343.9219 and 345.9297.







2l, (Z)-ethyl 4-(1-bromohex-1-en-1-yl)benzoate. Prepared according to General Procedure B from 4-(ethoxycarbonyl)phenylboronic acid (194 mg, 1 mmol) as a clear, orange oil (129 mg, 41% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.99 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 6.33 (t, J = 6.9 Hz, 1H), 4.38 (q, J

= 7.1 Hz, 2H), 2.39 (q, J = 7.2 Hz, 2H), 1.55 – 1.46 (m, 2H), 1.44 – 1.34 (m, 5H), 0.95 (t, J = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 166.05, 144.01, 133.88, 130.01, 129.46, 127.33, 124.24, 61.01, 32.39, 30.46, 22.43, 14.33, 13.94.

HRMS (ESI): for $C_{15}H_{20}BrO_2$, $[M+H]^+$ calculated m/z = 311.0642 and 313.0619, found m/z = 311.0641 and 313.0621.






2m, (Z)-1-(1-bromoprop-1-en-1-yl)-4-(trifluoromethyl)benzene. Prepared according to General Procedure A from 4'-(trifluoromethyl)propiophenone (606 mg, 3 mmol) as a clear, colorless oil (700 mg, 88% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.67 – 7.62 (m, 2H), 7.62 – 7.57 (m, 2H), 6.43 – 6.37 (m, 1H), 2.00 (d, J = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 143.35, 130.11 (q, *J* = 32.6 Hz), 128.50, 127.70, 125.22 (q, *J* = 3.8 Hz), 124.96, 121.81 (d, *J* = 271.8 Hz), 18.22.

¹⁹F NMR (471 MHz, CDCl₃) δ -62.63.

HRMS (EI): for C₁₀H₈BrF₃, $[M]^+$ calculated m/z = 263.9756 and 265.9736, found m/z = 263.9753 and 265.9732.







2n, (Z)-4-(1-bromobut-1-en-1-yl)benzonitrile. Prepared according to General Procedure B from 4-cyanophenylboronic acid (441 mg, 3 mmol) as a clear, yellow oil (153 mg, 21% yield).

¹H NMR (500 MHz, CDCl₃) δ 7.66 – 7.59 (m, 4H), 6.34 (t, J = 6.9 Hz, 1H), 2.45 – 2.33 (m, 2H), 1.13 (t, J = 7.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 144.04, 136.45, 132.05, 128.04, 122.79, 118.52, 111.71, 26.18, 12.66.

HRMS (ESI): for C₁₁H₁BrN, $[M+H]^+$ calculated m/z = 236.0069 and 238.0049, found m/z = 236.0070 and 238.0049.







20, (Z)-4-(1-bromohex-1-en-1-yl)benzonitrile. Prepared according to General Procedure B from 4-cyanophenylboronic acid (441 mg, 3 mmol) as a clear, yellow oil (357 mg, 45% yield).

¹H NMR (600 MHz, CDCl₃) δ 7.64 – 7.59 (m, 4H), 6.35 (t, *J* = 6.9 Hz, 1H), 2.39 (q, *J* = 7.2 Hz, 2H), 1.54 – 1.48 (m, 2H), 1.44 – 1.36 (m, 2H), 0.95 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 144.11, 135.21, 132.04, 128.04, 123.22, 118.52, 111.68, 32.44, 30.35, 22.41, 13.91. HRMS (ESI): for C₁₃H₁₅BrN, [M+H]⁺ calculated *m/z* = 264.0382 and 266.0362, found *m/z* = 264.0382 and 266.0361.






2p, (Z)-1-bromo-4-(1-bromoprop-1-en-1-yl)benzene. Prepared according to General Procedure A from 3'-


bromopropiophenone (213 mg, 1 mmol) as a clear, colorless oil (160 mg, 57% yield).

¹H NMR (500 MHz, CDCl₃) δ 7.46 (d, J = 9.1 Hz, 2H), 7.40 (d, J = 7.9 Hz, 2H), 6.30 (qd, J = 6.5, 0.9 Hz, 1H), 1.95 (d, J = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 139.02, 131.32, 128.99, 126.98, 125.35, 122.27, 18.22.

HRMS (EI): for C₉H₈Br₂, [M]⁺ calculated m/z = 273.8987 and 275.8967 and 277.8946, found m/z = 273.8986 and 275.8962 and 277.8943.







2q, (Z)-1-(1-bromoprop-1-en-1-yl)-3-chlorobenzene. Prepared according to General Procedure A from 3'-chloropropiophenone (169 mg, 1 mmol) as a clear, colorless oil (209 mg, 85%).

¹H NMR (500 MHz, CDCl₃) δ 7.54 – 7.50 (m, 1H), 7.44 – 7.38 (m, 1H), 7.30 – 7.23 (m, 2H), 6.33 (q, *J* = 6.7 Hz, 1H), 1.97 (d, *J* = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 142.02, 134.40, 129.66, 128.15, 125.87, 125.14, 18.44.

HRMS (EI): for C₉H₈BrCl, $[M]^+$ calculated m/z = 229.9492 and 231.9472, found m/z = 229.9492 and 231.9468.







2r, (Z)-4-(1-bromoprop-1-en-1-yl)-1-methyl-1H-pyrazole. Prepared according to General Procedure A from 1-(1-methyl-1H-pyrazol-4-yl)propan-1-one (138 mg, 1 mmol) as a clear, colorless oil (45 mg, 23% yield).

¹H NMR (600 MHz, CDCl₃) δ 7.56 (s, 1H), 7.44 (s, 1H), 6.16 (q, *J* = 6.6 Hz, 1H), 3.86 (s, 3H), 1.87 (d, *J* = 6.6 Hz, 3H).

 ^{13}C NMR (126 MHz, CDCl₃) δ 136.28, 129.13, 123.71, 122.19, 116.05, 39.03, 17.19.

HRMS (ESI): for $C_7H_{10}BrN_2$, $[M+H]^+$ calculated m/z = 201.0022 and 203.0001, found m/z = 201.0022 and 202.9999.







To a solution of 3'-hydroxypropiophene (750 mg, 5 mmol, 1 equiv) in DCM (10 mL, 0.5M) was added NEt₃ (2.1 mL, 15 mmol, 3 equiv) and DMAP (61 mg, 0.5 mmol, 0.1 equiv). The solution was cooled to 0 °C and Tf₂O (5.5 mL, 1M in DCM, 1.1 equiv) was added dropwise via syringe. The solution was stirred at 0 °C for 30 minutes and was then warmed to room temperature and stirred for an additional 3 hours. After this time, 1M HCl was added carefully, and the solution was diluted with Et₂O. The layers were separated, and the organic layer washed with 1M HCl (2x), water, NaHCO₃ (sat. aqueous), and brine. The organic layer was then dried over Na₂SO₄, concentrated in vacuo, and purified by column chromatography to afford 3-propionylphenyl trifluoromethanesulfonate (S1) as a clear, colorless oil (1.02 g, 72% yield).

¹H NMR (500 MHz, CDCl₃) δ 7.98 (ddd, J = 7.6, 1.5, 0.9 Hz, 1H), 7.86 (dd, J = 2.6, 1.5 Hz, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.47 (ddd, J = 8.2, 2.5, 1.0 Hz, 1H), 3.01 (q, J = 7.2 Hz, 2H), 1.25 (t, J = 7.2 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 198.45, 149.80, 139.10, 130.61, 127.76, 125.47, 120.73, 118.69 (q, J = 320.8 Hz), 32.02, 7.88. ¹⁹F NMR (471 MHz, CDCl₃) δ -72.80. HMMS (FSD) for C. H. F. O. S. [M + H]⁺ coloridated m/z = 282.0246, found m/z = 282.0246

HRMS (ESI): for $C_{10}H_{10}F_{3}O_{4}S$, $[M+H]^{+}$ calculated m/z = 283.0246, found m/z = 283.0246.





f1 (ppm)


2b, (Z)-3-(1-bromoprop-1-en-1-yl)phenyl trifluoromethanesulfonate was then prepared according to General Procedure A from **S1** (282 mg, 1 mmol) as a clear, colorless oil (214 mg, 62%).


¹H NMR (500 MHz, CDCl₃) δ 7.57 – 7.53 (m, 1H), 7.44 – 7.38 (m, 2H), 7.19 (dd, J = 8.3, 2.5 Hz, 1H), 6.37 (q, J = 6.6 Hz, 1H), 1.97 (d, J = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 149.35, 142.57, 129.94, 128.76, 127.21, 123.95, 120.76, 120.44, 118.73 (d, *J* = 320.7 Hz), 18.22.

¹⁹F NMR (471 MHz, CDCl₃) δ -72.83.

HRMS (EI): for $C_{10}H_8BrF_3O_3S$, [M]⁺ calculated m/z = 343.9324 and 345.9304, found m/z = 343.9325 and 345.9302.







(Z)-3-bromo-3-(4-nitrophenyl)prop-2-en-1-ol. **2s** was prepared according to a modified procedure by Shunatona, *et.* $al.^3$ *N,N*-Dimethylformamide (7.7 mL, 100 mmol, 5 equiv) was cooled to 0 °C in dichloromethane (100 mL, 0.2M). Phosphorus tribromide (8.2 mL, 86 mmol, 4.3 equiv) was added dropwise and the mixture was stirred at 0 °C for 2 h. 4-nitroacetophenone (3.3 g, 20 mmol) was dissolved in dichloromethane and was added via canula to the stirring mixture. The reaction mixture was heated at reflux at 40 °C for 12 h. The reaction mixture was poured over cold NaHCO₃, extracted with Et₂O, and dried over Na₂SO₄. The solvent was removed in vacuo to give aldehyde, which was taken directly to the next step.

A portion of the crude aldehyde was dissolved in EtOH (10 mL) at 0 °C. Cerium(III) chloride heptahydrate (1.3 g, 1.2 equiv) was then added all at once. Sodium borohydride (0.441 g, 12 mmol, 4 equiv) was carefully added. The reaction mixture was warmed to ambient temperature and stirred for 30 min. Upon completion the mixture was quenched with acetone and was stirred for 1 h. Saturated NH₄Cl was added to the reaction, and the solvent was removed under vacuum. The mixture was extracted with Et_2O , dried over Na₂SO₄, and the solvent was removed in vacuo. The crude product was filtered through a short pad of silica to give alcohol **2s** (686 mg, 91%) as a white solid.

¹H NMR (500 MHz, CDCl₃) δ 8.23 (dt, J = 9.4, 1.7 Hz, 2H), 7.74 (dt, J = 7.8, 0.9 Hz, 2H), 6.67 (td, J = 5.6, 1.1 Hz, 1H), 4.53 (t, J = 5.3 Hz, 2H), 1.85 – 1.71 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 147.79, 144.75, 134.15, 128.24, 123.66, 122.89, 63.38. HRMS (ESI): for C₉H₇BrNO₃, [M-H]⁺ calculated m/z = 255.9615 and 257.9594, found m/z = 255.9616 and 257.9595.






(Z)-1-bromo-3-(1,4-dibromobut-1-en-1-yl)benzene. **2t** was prepared according to a modified procedure by Murphy and coworker.⁴ To a flame-dried round-bottom flask equipped with a stir bar was added THF (40 mL, 0.1M) and NaHMDS (10.5 mL, 1M in THF, 2.1 equiv). The flask was then cooled to -78 °C and γ -butyrolactone (0.38 mL, 5 mmol, 1 equiv) was added dropwise via syringe. The reaction mixture was then stirred for 1 h. After this time, 3-bromobenzoylchloride (0.66 mL, 5 mmol, 1 equiv) was added via syringe, and the solution was stirred for 30 minutes. After this time, the reaction was quenched with 1M HCl and diluted with EtOAc. The organic layers were then washed with water and brine, dried over Na₂SO₄, and concentrated in vacuo to give the β -ketoester, which was used without further purification.


The crude β -ketoester was then dissolved in 1:1:1 THF:MeOH:H₂O (8 mL each) in a vial equipped with a stir bar and septum cap. Conc. HCl (~0.1 mL) was then added, and the vial sealed and heated to 65 °C. Upon completion by TLC, the mixture was cooled to room temperature, diluted with EtOAc, and washed with water and brine. The organic layer was then dried over Na₂SO₄ and concentrated in vacuo. The crude γ -hydroxyketone was then used without further purification.

The vinyl bromide was then synthesized according to General Procedure A without the DBU elimination as a clear, colorless oil (387 mg, 21% yield over 3 steps).

¹H NMR (500 MHz, CDCl₃) δ 7.68 (q, *J* = 1.9, 1.4 Hz, 1H), 7.46 (two overlapping dt, *J* = 12.5, 8.0, 2.1, 1.0 Hz, 2H), 7.22 (td, *J* = 7.9, 1.0 Hz, 1H), 6.31 (td, *J* = 6.7, 1.0 Hz, 1H), 3.52 (td, *J* = 6.8, 1.0 Hz, 2H), 2.95 (qd, *J* = 6.7, 1.0 Hz, 2H).


¹³C NMR (126 MHz, CDCl₃) δ 141.40, 131.70, 130.54, 129.79, 129.37, 126.25, 125.99, 122.36, 35.52, 30.65. HRMS (EI): for C₁₀H₉Br₃, [M]⁺ calculated *m/z* = 365.8249 and 367.8228 and 369.8208 and 371.8187, found *m/z* = 365.8247 and 367.8225 and 369.8204 and 371.8184.






Synthesis of Chiral Catalysts


General catalyst synthesis procedure:



The following procedure was modified from one reported by Banik, *et. al.*⁵ Diisopropyl azodicarboxylate (7.66 mL, 46.0 mmol, 2.30 equiv) was added dropwise via syringe over 10 minutes to a stirred suspension of methyl 3,5dihydroxy-4-iodobenzoate (1 equiv), triphenylphosphine (2.70 equiv), and the appropriate α -hydroxy ester (2.10 equiv) in tetrahydrofuran (0.1M) at 0 °C. The reaction mixture was warmed to room temperature. After 12 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (DCM), followed by an additional flash column chromatography purification (Hexanes:Et₂O).




dibenzyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2R,2'R)-bis(3-(4-(tertbutyl)phenyl)propanoate). 3b was isolated as a crystalline, white powder. ¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.11 (m, 28H), 6.84 (s, 2H), 5.09 (d, *J* = 1.5 Hz, 5H), 4.94 (dd, *J* = 8.0, 4.6 Hz, 2H), 3.75 (s, 3H), 3.39 - 3.21 (m, 6H), 1.29 (s, 16H). ¹³C NMR (126 MHz, CDCl₃) δ 170.03, 165.77, 157.91, 149.88, 135.01, 132.76, 130.48, 129.57, 129.31 – 128.07 (m), 125.36, 106.40, 86.15, 78.65, 67.13, 52.31, 38.43, 34.46, 31.37. HRMS (ESI): for C₄₈H₅₂IO₈, $[M+H]^+$ calculated m/z = 883.2701, found m/z = 883.2691. 400 11 300 200 100 0 Ř 7.5 7.0 6.5 6.0 5.5 5.0 4.5 3.5 3.0 2.5 2.0 1.5 1.0 4.0 f1 (ppm)





bis(4-(pentafluoro- λ^6 -sulfanyl)benzyl) 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2R,2'R)-bis(3-(4-(tert-butyl)phenyl)propanoate). **3c** was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.63 – 7.53 (m, 4H), 7.40 – 7.29 (m, 8H), 7.21 (d, *J* = 8.3 Hz, 4H), 6.80 (s, 2H), 5.15 – 5.05 (m, 4H), 4.97 (dd, *J* = 7.9, 4.6 Hz, 2H), 3.74 (s, 3H), 3.36 (dd, *J* = 14.0, 7.9 Hz, 2H), 3.30 (dd, *J* = 14.0, 4.6 Hz, 2H), 1.27 (s, 18H).


¹³C NMR (126 MHz, CDCl₃) δ 169.81, 165.49, 157.84, 153.58 (d, J = 17.0 Hz), 150.14, 138.77, 132.49, 131.50, 129.58, 128.17, 126.31 – 125.82 (m), 125.42, 106.33, 86.05, 78.55, 65.51, 52.33, 38.42, 34.45, 31.31. ¹⁹F NMR (471 MHz, CDCl₃) δ 84.16 (p, J = 150.3, 149.8 Hz, 1F), 62.77 (d, J = 149.6 Hz, 4F).









dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2R,2'R)-bis(3-phenylpropanoate) $^{1}H NMR (500 \text{ MHz}, \text{CDCl}_{3}) \\ \delta 7.46 - 7.39 \text{ (m, 4H)}, \\ 7.36 - 7.28 \text{ (m, 4H)}, \\ 7.28 - 7.22 \text{ (m, 2H)}, \\ 6.87 \text{ (s, 2H)}, \\ 4.93 \text{ (dd, 2H)}, \\ 6.87 \text{ (s, 2H)}, \\ 4.93 \text{ (dd, 2H)}, \\ 6.87 \text{ (s, 2H)}, \\$ J = 7.8, 4.6 Hz, 2H), 3.83 (s, 3H), 3.69 (s, 6H), 3.39 – 3.28 (m, 4H). **3d** was isolated as a crystalline, white powder. ¹³C NMR (126 MHz, CDCl₃) δ 170.51, 165.97, 158.03, 135.90, 131.60, 129.89, 128.45, 127.12, 106.40, 86.15, 78.69, 52.42, 39.01, 29.72.



HRMS (ESI): for $C_{28}H_{28}IO_8$, $[M+H]^+$ calculated m/z = 619.0823, found m/z = 619.0819.







dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(p-tolyl)propanoate). **3e** was isolated as a crystalline, white powder.


¹H NMR (500 MHz, CDCl₃) δ 7.32 (d, J = 8.0 Hz, 4H), 7.15 – 7.10 (m, 4H), 6.87 (s, 2H), 4.91 (dd, J = 7.7, 4.6 Hz, 2H), 3.85 (d, J = 0.5 Hz, 3H), 3.71 (d, J = 0.5 Hz, 6H), 3.39 – 3.22 (m, 5H), 2.33 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 170.57, 165.99, 158.05, 136.65, 132.80, 131.56, 129.76, 129.14, 106.34, 86.15, 78.81, 52.44, 52.39, 38.60, 21.12.

HRMS (ESI): for $C_{30}H_{32}IO_8$, $[M+H]^+$ calculated m/z = 647.1136, found m/z = 647.1129.










dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2R,2'R)-bis(3-(4-ethylphenyl)propanoate). **3e** was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.33 (d, J = 8.1 Hz, 3H), 7.14 (d, J = 7.8 Hz, 4H), 6.86 (s, 2H), 4.90 (dd, J = 7.9, 4.5 Hz, 2H), 3.83 (s, 2H), 3.69 (s, 6H), 3.36 – 3.23 (m, 4H), 2.62 (q, J = 7.6 Hz, 5H), 1.22 (t, J = 7.6 Hz, 5H). ¹³C NMR (126 MHz, CDCl₃) δ 170.60, 165.98, 158.06, 143.02, 133.09, 131.57, 129.83, 127.95, 106.35, 86.17, 78.82, 52.44, 52.40, 38.65, 28.52, 15.55.

HRMS (ESI): for $C_{32}H_{36}IO_8$, $[M+H]^+$ calculated m/z = 675.1149, found m/z = 675.1442.








dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2R,2'R)-bis(3-(4-


isopropylphenyl)propanoate). 3f was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.36 (d, *J* = 8.1 Hz, 4H), 7.18 (d, *J* = 8.1 Hz, 4H), 6.88 (s, 2H), 4.92 (dd, *J* = 8.0, 4.4 Hz, 2H), 3.85 (s, 3H), 3.71 (s, 6H), 3.32 (qd, *J* = 14.1, 6.2 Hz, 4H), 2.89 (p, *J* = 6.9 Hz, 2H), 1.25 (d, *J* = 6.9 Hz, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 170.65, 166.01, 158.06, 147.64, 133.25, 131.56, 129.81, 126.51, 106.36, 86.19, 78.82, 52.45, 52.41, 38.65, 33.78, 24.02.

HRMS (ESI): for $C_{34}H_{40}IO_8$, [M+H]⁺ calculated m/z = 703.1762, found m/z = 703.1751.






dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2R,2'R)-bis(3-(4-(tert-


butyl)phenyl)propanoate). 3g was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.34 (q, *J* = 8.3 Hz, 8H), 6.86 (s, 2H), 4.91 (dd, *J* = 8.2, 4.3 Hz, 2H), 3.83 (s, 3H), 3.70 (s, 6H), 3.31 (qd, *J* = 14.1, 6.2 Hz, 4H), 1.30 (s, 18H).

¹³C NMR (126 MHz, CDCl₃) δ 170.65, 165.97, 158.03, 149.90, 132.90, 131.54, 129.52, 125.36, 106.32, 86.17, 78.75, 52.42, 52.40, 38.52, 34.46, 31.36.

HRMS (ESI): for C₃₆H₄₄IO₈, $[M+H]^+$ calculated m/z = 731.2075, found m/z = 731.2066.







dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(4-adamantylphenyl)propanoate. **3h** was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.36 (d, J = 8.3 Hz, 4H), 7.29 (d, J = 8.3 Hz, 4H), 6.85 (s, 2H), 4.89 (dd, J = 8.2, 4.3Hz, 2H), 3.82 (s, 3H), 3.69 (s, 5H), 3.36 – 3.23 (m, 5H), 2.08 (s, 3H), 1.89 (d, *J* = 3.0 Hz, 14H), 1.81 – 1.69 (m, 16H).

¹³C NMR (126 MHz, CDCl₃) δ 170.67, 165.98, 158.05, 150.16, 132.97, 131.54, 129.58, 124.95, 106.35, 86.19, 78.80, 52.43, 52.40, 43.18, 38.58, 36.83, 36.00, 28.98.








dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(4-

(trifluoromethyl)phenyl)propanoate). 3i was isolated as a crystalline, white powder.


¹H NMR (500 MHz, CDCl₃) δ 7.56 (d, *J* = 1.6 Hz, 7H), 6.86 (s, 2H), 4.95 (dd, *J* = 7.2, 4.9 Hz, 2H), 3.84 (s, 3H), 3.71 (s, 6H), 3.47 – 3.35 (m, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 170.00, 165.78, 157.83, 139.92, 131.73, 130.31, 129.48 (q, *J* = 32.3 Hz), 125.36 (q, *J* = 3.8 Hz), 124.17 (q, *J* = 272.6, 272.0, 271.2 Hz), 106.45, 85.91, 78.03, 52.56, 52.50, 38.65. ¹⁹F NMR (471 MHz, CDCl₃) δ -65.09.


HRMS (ESI): for C₃₀H₂₆F₆IO₈, $[M+H]^+$ calculated m/z = 755.0571, found m/z = 755.0561.




-59.5 -60.0 -60.5 -61.0 -61.5 -62.0 -62.5 -63.0 -63.5 -64.0 -64.5 -65.0 -65.5 -66.0 -66.5 -67.0 -67.5 -68.0 -68.5 -69.0 -69.5 -70.0 -70.5 -71.0 -71.5 -72.0 -72.5 f1 (ppm)



dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(3,4,5-trifluorophenyl)propanoate). **3j** was isolated as a crystalline, white powder. ¹H NMR (500 MHz, CDCl₃) δ 7.11 (dd, *J* = 8.2, 6.4 Hz, 4H), 6.89 (s, 2H), 4.93 (t, *J* = 5.9 Hz, 2H), 3.88 (s, 3H), 3.74 (s, 6H), 3.30 (d, *J* = 5.8 Hz, 4H).



-124 -126 -128 -130 -132 -134 -136 -138 -140 -142 -144 -146 -148 -150 -152 -154 -156 -158 -160 -162 -164 -166 -168 -170 f1 (ppm)




dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(4-fluorophenyl)propanoate). **3k** was isolated as a crystalline, white powder.


¹H NMR (500 MHz, CDCl₃) δ 7.38 (dd, *J* = 8.6, 5.4 Hz, 4H), 6.99 (t, *J* = 8.7 Hz, 3H), 6.86 (s, 2H), 4.90 (dd, *J* = 7.2, 4.9 Hz, 3H), 3.84 (s, 3H), 3.69 (s, 6H), 3.38 – 3.24 (m, 4H).

¹³C NMR (126 MHz, CDCl₃) δ 170.26, 165.88, 163.05, 161.10, 157.94, 131.67, 131.47 (d, *J* = 8.0 Hz), 115.27 (d, *J* = 21.2 Hz), 106.41, 86.00, 78.49, 52.48, 52.45, 38.12.

 ^{19}F NMR (471 MHz, CDCl₃) δ -115.72.

HRMS (ESI): for $C_{28}H_{26}F_2IO_8$, $[M+H]^+$ calculated m/z = 655.0635, found m/z = 655.0630.







dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(4-chlorophenyl)propanoate). **31** was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.35 (d, *J* = 8.4 Hz, 4H), 7.26 (d, *J* = 8.0 Hz, 6H), 6.86 (s, 2H), 4.90 (t, *J* = 6.2 Hz, 3H), 3.83 (s, 3H), 3.69 (s, 6H), 3.35 – 3.25 (m, 4H).

¹³C NMR (126 MHz, CDCl₃) & 170.15, 165.85, 157.90, 134.29, 133.07, 131.69, 131.31, 128.58, 106.42, 85.98, 78.30, 52.51, 38.26.






dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(3-chlorophenyl)propanoate). 3m was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.47 (s, 2H), 7.29 (d, *J* = 4.7 Hz, 2H), 7.22 (d, *J* = 4.4 Hz, 4H), 6.86 (s, 2H), 4.91 (t, *J* = 6.0 Hz, 2H), 3.84 (s, 3H), 3.70 (s, 6H), 3.35 – 3.25 (m, 4H).

¹³C NMR (126 MHz, CDCl₃) δ 170.13, 165.86, 157.88, 137.75, 134.14, 131.63, 130.27, 129.67, 128.04, 127.38, 106.38, 85.92, 78.19, 52.52, 38.56.

HRMS (ESI): for C₂₈H₂₆Cl₂IO₈, $[M+H]^+$ calculated m/z = 687.0044, found m/z = 687.0040.





dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(m-tolyl)propanoate). **3n** was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.27 (s, 2H), 7.21 – 7.15 (m, 4H), 7.08 – 7.03 (m, 2H), 6.85 (s, 2H), 4.89 (dd, *J* = 7.9, 4.5 Hz, 2H), 3.83 (s, 3H), 3.69 (s, 6H), 3.34 – 3.23 (m, 5H), 2.34 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 170.57, 165.97, 158.06, 137.96, 135.82, 131.61, 130.87, 128.35, 127.88, 126.82, 106.33, 86.01, 78.79, 52.47, 52.41, 38.98, 21.41.

HRMS (ESI): for $C_{30}H_{32}IO_8$, $[M+H]^+$ calculated m/z = 647.1136, found m/z = 647.1132.






dimethyl 2,2'-((2-iodo-5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))(2S,2'S)-bis(3-(o-tolyl)propanoate). **30** was isolated as a crystalline, white powder.

¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.36 (m, 3H), 7.17 – 7.11 (m, 7H), 6.85 (s, 2H), 4.89 (dd, J = 8.4, 4.8 Hz, 3H), 3.83 (s, 3H), 3.69 (s, 6H), 3.40 – 3.27 (m, 5H), 2.43 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 170.76, 165.96, 158.09, 136.52, 134.28, 131.58, 130.81, 130.39, 127.26, 126.07, 106.51, 86.31, 78.12, 52.46, 36.12, 19.85.

HRMS (ESI): for $C_{30}H_{32}IO_8$, $[M+H]^+$ calculated m/z = 647.1136, found m/z = 647.1132.



 $methyl \ 3-(((S)-1-(benzyloxy)-3-(4-(tert-butyl)phenyl)-1-oxopropan-2-yl)oxy)-5-(((S)-1-((1S,2R)-2-bromo-1-fluoro-1-(3-nitrophenyl)propoxy)-3-(4-(tert-butyl)phenyl)-1-oxopropan-2-yl)oxy)-4-iodobenzoate (4)$

Isolated from crude reaction mixture as a minor component of the recovered catalyst, purified by repeated chromatography on SiO₂ with Hexanes/Et₂O and Hexanes/DCM. For characterization purposes, a modified reaction protocol was conducted to obtain larger quantities (30 mg, 28% yield): 242 mg substrate 88 mg catalyst 250 mg mCPBA (unpurified) 577 uL pyHF 2.3 mL DCM


Note: Relative stereochemistry of the bromostyrene-derived side-arm was not directly determined and is assigned on the basis of the major product enantiomer.


¹H NMR (500 MHz, Chloroform-*d*) δ 8.15 (dt, *J* = 7.7, 2.2 Hz, 1H), 7.97 (d, *J* = 2.3 Hz, 1H), 7.43 (d, *J* = 8.2 Hz, 2H), 7.38 (d, *J* = 8.1 Hz, 2H), 7.36 – 7.24 (m, 9H), 7.24 – 7.18 (m, 2H), 6.95 (s, 1H), 6.91 (s, 1H), 5.12 (s, 2H), 5.05 – 4.98 (m, 2H), 4.17 (dq, *J* = 13.6, 6.8 Hz, 1H), 3.80 (s, 3H), 3.48 – 3.24 (m, 4H), 1.39 (d, *J* = 5.9 Hz, 3H), 1.32 (s, 9H), 1.27 (s, 9H).

¹⁹F NMR (471 MHz, Chloroform-d) δ -117.34 (broad s).

¹³C NMR (126 MHz, Chloroform-*d*) δ 170.05, 166.47, 165.76, 158.41, 157.65, 150.47, 150.04, 148.07, 136.63 (d, *J* = 27.7 Hz), 135.12, 132.84, 132.05 (d, *J* = 7.0 Hz), 131.98, 131.95, 129.92, 129.70, 129.24, 128.62, 128.53, 125.65, 125.48, 124.49, 121.11 (d, *J* = 7.9 Hz), 111.41 (d, *J* = 242.4 Hz), 107.00, 105.94, 86.08, 78.82, 78.32, 67.34, 52.62, 49.37 (d, *J* = 29.0 Hz), 38.51, 38.34, 36.77, 34.65, 34.57, 31.51, 31.48, 19.57 (d, *J* = 3.0 Hz).

HRMS (ESI): for $C_{50}H_{53}BrFINO_{10}$, $[M+H]^+$ calculated m/z = 1052.1876 and 154.1856, found m/z = 1052.1869 and 1054.1863.








Figure S1. Catalyst structure-activity relationship study. Enantiomeric excesses were obtained using substrate **2a** under the standard conditions (*vide infra*). Methyl-ester-substituted catalysts did not undergo decomposition to iodoarenes analogous to **4**. These catalysts offered lower yields of product **1a** but with comparable enantioselectivities (cf. **3b** vs. **3g**) and were employed in the SAR study due to their simpler preparation.




Figure S2. 9HF · Pyridine loading optimization




Figure S3. Para-Adamantyl Catalyst Effect




Figure S4. ¹H NMR spectrum of crude reaction mixture of fluorination of **2a** catalyzed by **3b** (20 mol%). Catalyst decomposition product **4** resonances can be observed at 6.94 ppm and 6.90 ppm.




Figure S5. ¹⁹F NMR spectrum of crude reaction mixture of fluorination of **2a** catalyzed by **3b** (20 mol%). Catalyst decomposition product **4** resonance can be observed at -117.37 ppm.




Figure S6. ¹H NMR spectrum of crude reaction mixture of fluorination of **2a** catalyzed by **3b** (10 mol%). Catalyst decomposition product's (**4**) diagnostic resonances can be observed at 6.94 ppm and 6.90 ppm. Parent catalyst's (**3b**) diagnostic resonance at 6.83 ppm is barely observable. Significant starting material (~6.45 ppm) remains.




Figure S7. ¹H NMR spectrum of crude reaction mixture of fluorination of **2a** catalyzed by **3c** (10 mol%). No catalyst decomposition products analogous to **4** are observed.






Figure S8. ¹⁹F NMR spectrum of crude reaction mixture of fluorination of **2a** catalyzed by **3c** (10 mol%). No catalyst decomposition products analogous to **4** are observed.

General Procedure for Oxidative Rearrangement



To a solution of substrate (0.2 mmol, 1 equiv) and catalyst **3c** (23 mg, 0.02 mmol, 10 mol%) in dichloromethane (2.3 mL) in a low-density polyethylene tube at -78 °C was added HF•Pyridine (py•9HF, 70% hydrogen fluoride by weight, 577 µL, 100 equiv hydrogen fluoride) followed by *m*CPBA⁶ (41.4 mg, 0.24 mmol, 1.2 equiv). The reaction was warmed to -40 °C and stirred at that temperature for 48 hours. The heterogeneous mixture was then cooled to -78 °C and transferred carefully into a vigorously stirred suspension of basic alumina (2.0 g) in dichloromethane at -78 °C. The resulting suspension was allowed to warm to room temperature and was filtered through addition basic alumina, washing with 10 mL dichloromethane. The combined filtrate was concentrated in vacuo and purified by column chromatography.

Racemic samples were prepared using the same procedure with the following modification: Iodobenzene or iodotoluene (20 mol%) were used in place of 3c.




(R)-1-(2-bromo-1,1-difluoropropyl)-3-nitrobenzene. **1a** was prepared from **2a** (48.4 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (47.1 mg, 84% yield).


¹H NMR (500 MHz, CDCl₃) δ 8.40 (s, 1H), 8.36 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.67 (t, J = 8.0 Hz, 1H), 4.47 – 4.27 (m, 1H), 1.79 (d, J = 6.9 Hz, 3H).


¹³C NMR (126 MHz, CDCl₃) δ 148.04, 136.14 (t, *J* = 27.8 Hz), 132.18 (t, *J* = 5.9 Hz), 129.58, 125.31, 121.54 (t, *J* = 6.5 Hz), 119.31 (dd, *J* = 248.1, 247.1 Hz), 47.33 (t, *J* = 32.9 Hz), 19.19 (t, *J* = 3.1 Hz).

¹⁹F NMR (471 MHz, CDCl₃) δ -97.75 (d, *J* = 248.0 Hz, 1F), -104.67 (d, *J* = 247.7 Hz, 1F).

HRMS (EI): for C₉H₈BrF₂NO₂, [M]⁺ calculated m/z = 278.9701 and 280.9681, found m/z = 278.9700 and 280.9679 Chiral HPLC: Chiralpak AS-H, 1.2% isopropanol/hexanes, 0.5 ml/min; 92% ee








(R)-3-(2-bromo-1,1-difluoropropyl)phenyl trifluoromethanesulfonate. **1b** was prepared from **2b** (69.0 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (62.1 mg, 81% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.58 – 7.55 (m, 2H), 7.46 – 7.43 (m, 1H), 7.43 – 7.38 (m, 1H), 4.37 – 4.27 (m, 1H), 1.74 (d, *J* = 6.9 Hz, 3H).


¹³C NMR (126 MHz, CDCl₃) δ 149.20, 136.80 (t, J = 27.7 Hz), 130.35, 126.16 (t, J = 6.0 Hz), 123.39, 119.75 (t, J = 6.5 Hz), 119.22 (t, J = 249.7 Hz), 118.71 (q, J = 321.3 Hz) 47.44 (t, J = 32.8 Hz), 19.28 (t, J = 3.1 Hz).

¹⁹F NMR (471 MHz, CDCl₃) δ -72.69 (s, 3F), -98.94 (d, *J* = 247.2 Hz, 1F), -103.19 (d, *J* = 247.0 Hz, 1F).

HRMS (EI): for C₁₀H₈BrF₅O₃S, [M]⁺ calculated m/z = 381.9292 and 383.9272, found m/z = 381.9292 and 383.9270 Chiral GC: CP-Chirasil-Dex CB, isothermal, 14 psi, 79% ee







(R)-ethyl 3-(2-bromo-1,1-difluorobutyl)benzoate. 1c was prepared from 2c (56.6 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (50.1 mg, 78% yield).

¹H NMR (500 MHz, CDCl₃) δ 8.20 – 8.16 (m, 1H), 8.15 (dt, *J* = 7.5, 1.3 Hz, 1H), 7.74 – 7.68 (m, 1H), 7.53 (ddt, *J* = 7.8, 7.0, 0.8 Hz, 1H), 4.41 (q, *J* = 7.2 Hz, 2H), 4.17 (qd, *J* = 11.0, 2.8 Hz, 1H), 2.12 – 2.02 (m, 1H), 1.82 – 1.69 (m, 1H), 1.42 (td, *J* = 7.1, 0.8 Hz, 3H), 1.14 – 1.05 (m, 3H).


¹³C NMR (126 MHz, CDCl₃) δ 165.72, 135.04 (t, *J* = 26.9 Hz), 131.36, 130.84, 130.34 (t, *J* = 6.0 Hz), 128.43,


127.08 (t, *J* = 6.3 Hz), 119.81 (t, *J* = 247.5 Hz), 61.39, 57.28 (t, *J* = 31.2 Hz), 25.23, 14.31, 12.21.


¹⁹F NMR (471 MHz, CDCl₃) δ -98.58 (d, *J* = 246.1 Hz, 1F), -100.55 (d, *J* = 246.8 Hz, 1F).

HRMS (ESI): for C₁₃H₁₆BrF₂O₂, $[M+H]^+$ calculated m/z = 321.0296 and 323.0276, found m/z = 321.0297 and 323.0276.

Chiral HPLC: Chiralpak IB, 0.3% isopropanol/hexanes, 1.0 ml/min, 89% ee










(R)-ethyl 3-(2-bromo-1,1-difluorohexyl)benzoate. 1d was prepared from 2d (62.2 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (58.7 mg, 84% yield).

¹H NMR (500 MHz, CDCl₃) δ 8.17 (s, 1H), 8.15 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 7.7 Hz, 1H), 7.53 (t, J = 7.8 Hz, 2H), 4.41 (q, J = 7.1 Hz, 3H), 4.22 (qd, J = 11.2, 2.8 Hz, 2H), 2.04 – 1.93 (m, 1H), 1.76 (dddd, J = 14.2, 11.0, 9.5, 4.5 Hz, 1H), 1.62 (tt, J = 9.9, 5.4 Hz, 1H), 1.42 (t, J = 7.1 Hz, 3H), 1.39 – 1.21 (m, 4H), 0.89 (t, J = 7.2 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 165.73, 135.06 (t, J = 26.9 Hz), 131.35, 130.83, 130.36 (t, J = 6.0 Hz), 128.42, 127.10 (t, J = 6.3 Hz), 119.86 (t, J = 247.6 Hz), 61.38, 55.31 (t, J = 31.4 Hz), 31.30, 29.43, 21.83, 14.31, 13.79. ¹⁹F NMR (471 MHz, CDCl₃) δ -97.93 (d, J = 246.3 Hz, 1F), -100.49 (d, J = 246.2 Hz, 1F). HRMS (ESI): for C₁₅H₂₀BrF₂O₂, [M+H]⁺ calculated m/z = 349.0609 and 351.0589, found m/z = 349.0608 and 351.0587.

Chiral HPLC: Chiralpak IB, 0.8% isopropanol/hexanes, 1.0 ml/min, 82% ee








(R)-1-(2-bromo-1,1-difluoropropyl)-3-(trifluoromethyl)benzene. **1e** was prepared from **2e** (53.0 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (36.4 mg, 60% yield).

¹H NMR (500 MHz, CDCl₃) δ 7.81 – 7.72 (m, 3H), 7.64 – 7.59 (m, 1H), 4.42 – 4.31 (m, 1H), 1.76 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 135.13 (t, J = 27.2 Hz), 130.95 (q, J = 33.1 Hz), 129.56 (t, J = 6.1 Hz), 128.94, 127.24 (d, J = 4.1 Hz), 124.70 (q, J = 272.7, 271.2 Hz), 123.14 (tt, J = 7.2, 3.6 Hz), 119.80 (dd, J = 249.0, 248.4 Hz), 47.68 (t, J = 32.9 Hz), 19.34.

¹⁹F NMR (471 MHz, CDCl₃) δ -62.81 (s, 3F), -99.59 (d, *J* = 247.5 Hz, 1F), -103.00 (d, *J* = 247.9 Hz, 1F).


¹⁹F NMR (471 MHz, Chloroform-*d*) δ -62.81, -99.59 (d, J = 247.5 Hz), -103.00 (d, J = 247.9 Hz). HRMS (EI): for C₁₀H₈BrF₅, [M]⁺ calculated m/z = 301.9724 and 303.9704, found m/z = 301.9722 and 303.9700 Chiral GC: CP-Chirasil-Dex CB, 40 °C to 110 °C, 1 °C/min, 7 psi, 80% ee






min

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[pA*s]	[pA]	olo
1	60.931	MF	0.1863	181.12358	16.20064	49.68198
2	61.476	FM	0.1954	183.44238	15.64308	50.31802






(R)-3-(2-bromo-1,1-difluorohexyl)benzonitrile. **1f** was prepared from **2f** (52.8 mg, 0.2 mmol) according the General Procedure as a clear, colorless oil (39.3 mg, 65% yield).

¹H NMR (500 MHz, CDCl₃) δ 7.82 (s, 1H), 7.80 – 7.73 (m, 2H), 7.61 – 7.56 (m, 1H), 4.17 (qd, *J* = 11.1, 2.7 Hz, 1H), 2.08 – 1.97 (m, 1H), 1.78 – 1.58 (m, 2H), 1.47 – 1.27 (m, 3H), 0.92 (t, *J* = 7.2 Hz, 3H).


¹³C NMR (126 MHz, CDCl₃) δ 136.15 (t, J = 27.5 Hz), 133.83, 130.52 (t, J = 6.1 Hz), 130.00 (t, J = 6.4 Hz), 129.23, 119.36 (t, J = 248.9 Hz), 117.94, 112.78, 54.64 (t, J = 31.5 Hz), 31.18, 29.38, 21.83, 13.79.

¹⁹F NMR (471 MHz, CDCl₃) δ -96.08 (d, J = 248.2 Hz, 1F), -103.11 (d, J = 248.6 Hz, 1F).

HRMS (ESI): for $C_{13}H_{15}BrF_2N$, $[M+H]^+$ calculated m/z = 302.0350 and 304.0330, found m/z = 302.0348 and 304.0327 Chiral HPLC: Chiralpak AS-H, 1.0% isopropanol/hexanes, 1.0 ml/min, 81% ee



-	10.000		0.1202	0.0000001	1100.01010	10.0000
2	18.751	FM	0.6433	3.49399e4	905.23975	51.1302




(R)-1-bromo-3-(2-bromo-1,1-difluorobutyl)benzene. **1g** was prepared from **2g** (58.0 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (34.1 mg, 52% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.66 (t, *J* = 1.9 Hz, 1H), 7.60 (dd, *J* = 7.8, 2.0 Hz, 1H), 7.45 (d, *J* = 7.6 Hz, 1H), 7.32 (t, *J* = 7.9 Hz, 1H), 4.11 (qd, *J* = 11.2, 2.7 Hz, 1H), 2.18 – 1.95 (m, 1H), 1.83 – 1.66 (m, 1H), 1.09 (td, *J* = 7.4, 1.7 Hz, 3H).


¹³C NMR (126 MHz, CDCl₃) δ 136.59 (t, *J* = 27.0 Hz), 133.47, 129.87, 129.21, 124.78 (t, *J* = 6.2 Hz), 122.40, 119.36 (t, *J* = 247.9 Hz), 57.14 (t, *J* = 31.1 Hz), 25.24 (t, *J* = 2.5 Hz), 12.23.


¹⁹F NMR (471 MHz, CDCl₃) δ -98.29 (d, J = 246.3 Hz), -99.83 (d, J = 246.3 Hz).

HRMS (EI): for $C_{10}H_{10}Br_2F_2$, [M]⁺ calculated m/z = 325.9112 and 327.9091 and 329.9071, found m/z = 325.9109 and 327.9087 and 329.9066











(R)-1-bromo-3-(2-bromo-1,1-difluoro-3-methylbutyl)benzene. **1h** was prepared from **2h** (60.8 mg, 0.2 mmol) according to General Procedure A as a clear, colorless oil (49.9 mg, 73% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.65 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 4.20 (ddd, J = 15.3, 13.3, 2.3 Hz, 1H), 2.02 (pd, J = 6.5, 2.2 Hz, 1H), 1.03 (dd, J = 6.6, 3.5 Hz, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 137.51 (t, J = 27.0 Hz), 133.48, 130.06, 128.79 (t, J = 6.5 Hz), 124.34 (t, J = 6.0 Hz), 122.59, 119.64 (t, J = 249.0 Hz), 63.21 (dd, J = 29.9, 27.6 Hz), 28.73, 22.58, 17.79.

¹⁹F NMR (471 MHz, CDCl₃) δ -95.43 (d, J = 245.7 Hz), -98.59 (d, J = 247.1 Hz). HRMS (EI): for $C_{11}H_{12}Br_2F_2$, $[M]^+$ calculated m/z = 339.9268 and 341.9248 and 343.9227, found m/z = 339.9261 and 341.9240 and 343.9219

Chiral GC: CP-Chirasil-Dex CB, 80 °C to 105 °C, 0.5 °C/min, 14 psi, 70% ee







(R)-1-(2-bromo-1,1-difluorobutyl)-4-nitrobenzene. 1i was prepared from 2i (51.2 mg, 0.2 mmol) according to the General Procedure as a white solid (48.8 mg, 83% yield).

¹H NMR (500 MHz, CDCl₃) δ 8.31 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 9.0 Hz, 2H), 4.14 (dddd, J = 13.9, 11.4, 8.7, 2.8 Hz, 1H), 2.20 – 2.07 (m, 1H), 1.76 (dddd, J = 14.6, 10.9, 7.3, 1.2 Hz, 1H), 1.12 (t, J = 7.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 149.08, 140.72 (t, J = 27.0 Hz), 127.52, 123.44, 119.49 (t, J = 247.8 Hz), 56.46 (t, J = 30.9 Hz), 25.10, 12.14.

¹⁹F NMR (471 MHz, CDCl₃) δ -100.99 (dd, J = 248.4, 6.3 Hz, 1F), -107.86 (dd, J = 248.8, 9.4 Hz, 1F). HRMS (EI): for C₁₀H₁₀BrF₂NO₂, [M]⁺ calculated m/z = 292.9857 and 294.9837, found m/z = 292.9857 and 294.9835 Chiral HPLC: Chiralcel OD-H, 1.0% isopropanol/hexanes, 1.0 ml/min, 92% ee





Bu Ēr O₂N

(R)-1-(2-bromo-1,1-difluorohexyl)-4-nitrobenzene. 1j was prepared from 2j (56.8 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (54.1 mg, 84% yield).


¹H NMR (500 MHz, CDCl₃) δ 8.33 (d, J = 8.5 Hz, 2H), 7.74 (d, J = 8.8 Hz, 2H), 4.21 (dddd, J = 14.0, 11.3, 8.6, 2.8 Hz, 1H), 2.11 – 1.97 (m, 1H), 1.83 – 1.60 (m, 2H), 1.48 – 1.24 (m, 3H), 0.93 (t, J = 7.2 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 139.07 (t, *J* = 27.1 Hz), 132.07, 127.09 (t, *J* = 6.2 Hz), 119.50 (t, *J* = 248.1 Hz),


117.89, 114.46, 54.56 (t, *J* = 31.3 Hz), 31.18, 29.37, 21.82, 13.78.

¹⁹F NMR (471 MHz, CDCl₃) δ -96.13 (d, J = 248.2 Hz, 1F), -103.17 (d, J = 248.1 Hz, 1F).

HRMS (EI): for $C_{12}H_{14}BrF_2NO_2$, [M]⁺ calculated m/z = 321.0170 and 323.0150, found m/z = 321.0168 and 323.0147 Chiral HPLC: Chiralcel OB-H, 0.5% isopropanol/hexanes, 1.0 ml/min, 93% ee



Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	0/0
1	20.701	FM	0.7937	2.66454e4	559.55054	50.7911
2	24.376	BV	0.9300	2.58154e4	419.48834	49.2089




1	20.438	MM	0.4996	2.66255e4	888.26093	96.5493
2	22.930	MM	0.6040	951.61267	26.25781	3.4507


(R)-4-(2-bromo-1,1-difluoropropyl)phenyl trifluoromethanesulfonate. **1k** was prepared from **2k** (69.0 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (61.3 mg, 80% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, *J* = 8.3 Hz, 2H), 7.38 (d, *J* = 8.5 Hz, 2H), 4.41 – 4.30 (m, 1H), 1.75 (d, *J* = 7.1 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 150.66, 134.49 (t, *J* = 27.2 Hz), 128.48 (t, *J* = 6.1 Hz), 121.34, 119.54 (t, *J* = 248.3, 246.9 Hz), 118.32 (q, *J* = 321.3, 320.7, 319.9 Hz), 47.63 (t, *J* = 32.9 Hz), 19.34.


¹⁹F NMR (471 MHz, CDCl₃) δ -72.78 (s, 3F), -98.92 (d, J = 247.1 Hz, 1F), -102.80 (d, J = 247.1 Hz, 1F). HRMS (EI): for C₁₀H₈BrF₅O₃S, [M]⁺ calculated m/z = 381.9292 and 383.9272, found m/z = 381.9293 and 383.9271 Chiral GC: CP-Chirasil-Dex CB, 40 °C to 200 °C, 1 °C/min, 7 psi, 80% ee








Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[pA*s]	[pA]	0/0
1	104.016	MM	0.1455	45.72702	5.23653	49.88974
2	104.656	MM	0.1493	45.92914	5.12594	50.11026



	RetTime [min]			Area [pA*s]	Height [pA]	Area %
1	96.814	MF	0.1451	23.20891	2.66577	10.17903
2	97.165	FM	0.2567	204.79826	13.29851	89.82097



(R)-ethyl 4-(2-bromo-1,1-difluorohexyl)benzoate. 11 was prepared from 21 (62.2 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (58.7 mg, 84% yield).


¹H NMR (500 MHz, CDCl₃) δ 8.12 (d, J = 8.1 Hz, 2H), 7.69 – 7.52 (m, 2H), 4.40 (q, J = 7.1 Hz, 2H), 4.20 (qd, J = 11.3, 2.8 Hz, 1H), 1.96 (dddd, J = 14.4, 9.9, 5.9, 2.7 Hz, 1H), 1.73 (dddd, J = 14.3, 11.1, 9.5, 4.5 Hz, 1H), 1.62 (qt, J = 9.7, 5.5 Hz, 1H), 1.41 (t, J = 7.1 Hz, 3H), 1.39 – 1.22 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 165.75, 138.69 (t, *J* = 26.5 Hz), 132.33, 129.45, 126.18 (t, *J* = 6.1 Hz), 119.87 (t, *J* = 248.1, 247.3 Hz), 61.34, 55.14 (t, *J* = 31.2 Hz), 31.33, 29.42, 21.82, 14.30, 13.78.

¹⁹F NMR (471 MHz, CDCl₃) δ -98.56 (d, J = 245.7 Hz, 1F), -100.55 (d, J = 245.9 Hz, 1F).


HRMS (ESI): for C₁₅H₂₀BrF₂O₂, $[M+H]^+$ calculated m/z = 349.0609 and 351.0589, found m/z = 349.0607 and 351.0585.

Chiral HPLC: Chiralcel OJ-H, 0.3% isopropanol/hexanes, 0.5 ml/min, 79% ee



Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak RetTime Type		Height	Area			
# [min] 	[min] [mAU*s]	[mAU]	% 			
1 16.491 MM	0.5157 1.98743e4	642.25793	47.8168			
2 17.672 FM	0.5901 2.16891e4	612.54230	52.1832			
	Sig=230,4 Ref=450,100 (JO\A	BC 2010 06 24 16 2	5 29\ 10 2 41 0			1
mAU =	, Sig-230,4 Kei-430, 100 (JOVA	BC 2019-00-24 10-2	5-26\JU-3-41_U	/		
400 -				18.649		
300 -						
200 -				Q		
100				17.406		
0						
	5	10	15	20	25	min
Signal 3: DAD1 C,	Sig=230,4 Ref=450,	100				
Peak RetTime Type	Width Area	Height	Area			
# [min]	[min] [mAU*s]	[mAU]	% 			
1 1	0.4952 2196.47729		10.3406			
2 18.649 VB	0.5430 1.90449e4	520.37158	89.6594			




(R)-1-(2-bromo-1,1-difluoropropyl)-4-(trifluoromethyl)benzene. **1m** was prepared from **2m** (53.0 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (33.3 mg, 55% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.74 (d, *J* = 8.3 Hz, 2H), 7.67 (d, *J* = 8.2 Hz, 2H), 4.37 (ddq, *J* = 12.2, 10.1, 6.9 Hz, 1H), 1.76 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 137.71 (t, J = 26.8 Hz), 132.55 (q, J = 32.4, 31.7 Hz), 126.73 (t, J = 6.1 Hz), 125.34 (q, J = 3.8 Hz), 123.61 (q, J = 272.4 Hz), 119.81 (t, J = 247.9, 247.2 Hz), 47.64 (t, J = 32.8 Hz), 19.35.


¹⁹F NMR (471 MHz, CDCl₃) δ -62.96 (d, J = 4.9 Hz, 3F), -99.90 (d, J = 246.5 Hz, 1F), -103.12 (d, J = 246.4 Hz, 1F).

HRMS (EI): for $C_{10}H_8BrF_5$, [M]⁺ calculated m/z = 301.9724 and 303.9704, found m/z = 301.9721 and 303.9700 Chiral GC: CP-Chirasil-Dex CB, 40 °C to 200 °C, 1 °C/min, 7 psi, 83% ee





S69




(R)-4-(2-bromo-1,1-difluorobutyl)benzonitrile. **1n** was prepared from **2n** (47.2 mg, 0.2 mmol) according to the General Procedure as a white solid (40.0 mg, 73% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.82 – 7.72 (m, 2H), 7.64 (d, J = 8.6 Hz, 2H), 4.11 (dddd, J = 13.7, 10.9, 9.0, 2.8 Hz, 1H), 2.10 (dqd, J = 14.5, 7.3, 2.9 Hz, 1H), 1.84 – 1.67 (m, 1H), 1.11 (t, J = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 139.07 (t, *J* = 27.1 Hz), 132.08, 127.07 (t, *J* = 6.2 Hz), 119.46 (dd, *J* = 249.2, 248.3 Hz), 117.88, 114.48, 56.50 (t, *J* = 31.1 Hz), 25.11, 12.17.

¹⁹F NMR (471 MHz, CDCl₃) δ -97.02 (d, J = 248.2 Hz), -103.09 (d, J = 248.2 Hz).

HRMS (EI): for $C_{11}H_{10}BrF_2N$, $[M]^+$ calculated m/z = 272.9959 and 274.9939, found m/z = 272.9963 and 274.9942. Chiral GC: CP-Chirasil-Dex CB, isothermal 140 °C, 7 psi, 89% ee






(R)-4-(2-bromo-1,1-difluorohexyl)benzonitrile. **10** was prepared from **20** (52.8 mg, 0.2 mmol) according to the General Procedure as a white solid (45.9 mg, 76% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.75 (d, *J* = 8.8 Hz, 2H), 7.64 (d, *J* = 8.4 Hz, 2H), 4.17 (dddd, *J* = 13.7, 11.4, 8.8, 2.7 Hz, 1H), 2.01 (dddd, *J* = 14.3, 9.8, 5.8, 2.7 Hz, 1H), 1.79 – 1.58 (m, 2H), 1.45 – 1.18 (m, 3H), 0.91 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 139.08 (t, J = 27.3 Hz), 132.07, 127.09 (t, J = 6.2 Hz), 119.50 (t, J = 248.2 Hz), 117.89, 114.47, 54.55 (t, J = 31.3 Hz), 31.18 (t, J = 2.4 Hz), 29.37, 21.82, 13.78.

¹⁹F NMR (471 MHz, CDCl₃) δ -96.86 (d, *J* = 247.8 Hz), -103.21 (d, *J* = 246.7 Hz).

HRMS (EI): for $C_{13}H_{14}BrF_2N$, [M]⁺ calculated m/z = 301.0272 and 303.0252, found m/z = 301.0272 and 303.0251 Chiral GC: CP-Chirasil-Dex CB, 40 °C to 200 °C, 1 °C/min, 88% ee





Br

(R)-1-bromo-4-(2-bromo-1,1-difluoropropyl)benzene. **1p** was prepared from **2p** (55.2 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (50.9 mg, 81% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.59 (d, J = 8.3 Hz, 2H), 7.41 – 7.36 (m, 2H), 4.32 (tq, J = 11.0, 6.9 Hz, 1H), 1.71 (d, J = 6.9 Hz, 3H).


¹³C NMR (126 MHz, CDCl₃) δ 133.03 (t, J = 27.1 Hz), 131.56, 127.79 (t, J = 6.1 Hz), 124.93 (d, J = 2.2 Hz), 119.88 (t, J = 247.5 Hz), 47.99 (t, J = 33.1 Hz), 19.46 (t, J = 3.1 Hz).


¹⁹F NMR (376 MHz, CDCl₃) δ -102.30 (dd, J = 245.5, 10.9 Hz, 1F), -103.81 (dd, J = 245.1, 11.5 Hz, 1F).

HRMS (EI): for C₉H₈Br₂F₂, [M]⁺ calculated m/z = 311.8955 and 313.8935 and 315.8914, found m/z = 311.8954 and 313.8932 and 315.8911

Chiral GC: CP-Chirasil-Dex CB, 40 °C to 160 °C, 0.5 °C/min, 7 psi, 82% ee









(R)-1-(2-bromo-1,1-difluoropropyl)-3-chlorobenzene. **1q** was prepared from **2q** (46.3 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (38.3 mg, 71% yield).

¹H NMR (500 MHz, CDCl₃) δ 7.51 (t, J = 0.6 Hz, 1H), 7.48 – 7.43 (m, 1H), 7.42 – 7.37 (m, 2H), 4.32 (tq, J = 11.3, 7.0 Hz, 1H), 1.72 (d, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 135.93 (t, *J* = 27.1 Hz), 134.49, 130.60, 129.67, 126.39 (t, *J* = 6.5 Hz), 124.30 (t, *J* = 6.1 Hz), 119.45 (t, *J* = 247.7 Hz), 47.89 (t, *J* = 32.7 Hz), 19.46.

¹⁹F NMR (471 MHz, CDCl₃) δ -103.22 (dd, J = 245.3, 11.0 Hz, 1F), -104.31 (dd, J = 245.1, 11.5 Hz, 1F). HRMS (EI): for C₉H₈BrClF₂, [M]⁺ calculated m/z = 267.9460 and 269.9440, found m/z = 267.9459 and 269.9434. Chiral GC: β-Cyclosil, 40 °C to 140 °C, 0.5 °C/min, 7 psi, 79% ee





MeN Br


(R)-4-(2-bromo-1,1-difluoropropyl)-1-methyl-1H-pyrazole. **1r** was prepared from **2r** (40.2 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (39.2 mg, 82% yield).


¹H NMR (500 MHz, CDCl₃) δ 7.60 (s, 1H), 7.57 (s, 1H), 4.39 – 4.24 (m, 1H), 3.94 (s, 3H), 1.71 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 137.55, 129.52 (t, *J* = 5.4 Hz), 118.71 (t, *J* = 241.9 Hz), 116.20 (t, *J* = 31.7 Hz), 48.36 (t, *J* = 34.1 Hz), 39.24, 19.62.

¹⁹F NMR (471 MHz, CDCl3) δ -93.66 (dd, J = 253.8, 6.3 Hz, 1F), -96.41 (dd, J = 254.8, 10.0 Hz, 1F).

HRMS (ESI): for C₇H₁₀BrF₂N₂, $[M+H]^+$ calculated m/z = 238.9990 and 240.9969, found m/z = 238.9989 and 240.9965.

Chiral GC: CP-Chirasil-Dex CB, isothermal 110 °C, 7 psi, 63% ee





	RetTime [min]			Area [pA*s]	Height [pA]	Area %
	2 3		2 3	-1 3		
1	28.075	MF	0.2886	45.05552	2.60222	18.52708
2	28.715	FM	0.5021	198.13184	6.57730	81.47292

(R)-2-bromo-3,3-difluoro-3-(4-nitrophenyl)propan-1-ol. **1s** was prepared from **2s** (51.6 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (44.4 mg, 75% yield).


¹H NMR (399 MHz, CDCl₃) δ 8.33 (d, *J* = 9.1 Hz, 1H), 7.73 (d, *J* = 8.8 Hz, 2H), 4.40 (dddd, *J* = 14.8, 8.9, 7.3, 4.1 Hz, 1H), 4.19 – 4.03 (m, 1H), 3.99 – 3.83 (m, 1H), 1.98 (s, 1H).


¹³C NMR (126 MHz, CDCl₃) δ 149.23, 140.18 (t, *J* = 26.7 Hz), 127.33 (t, *J* = 6.2 Hz), 123.65, 119.01 (t, *J* = 249.9, 248.6 Hz), 62.23 (t, *J* = 3.2 Hz), 56.99 - 52.11 (m).

¹⁹F NMR (471 MHz, CDCl₃) δ -95.15 (d, J = 252.0 Hz), -101.92 (d, J = 252.2 Hz).


HRMS (ESI): for C₉H₉BrF₂NO₃, $[M+H]^+$ calculated m/z = 293.9583 and 295.9562, found m/z = 293.9583 and 295.9560.

Chiral HPLC: Chiralpak IA, 8.0% isopropanol/hexanes, 1.0 ml/min, 90% ee





	110011110	- 11		111 0 04		1111 0 04	
#	[min]		[min]	[mAU*s]	[mAU]	8	
1	22.716	MM	0.7829	1099.70837	23.41049	95.0530	
2	28.253	MM	0.9952	57.23410	9.58472e-1	4.9470	




(R)-1-bromo-3-(2,4-dibromo-1,1-difluorobutyl)benzene. **1t** was prepared from **2t** (73.8 mg, 0.2 mmol) according to the General Procedure as a clear, colorless oil (79.8 mg, 98% yield). Enantiomeric excess was determined from the thioacetate substitution product. See S2 below.


¹H NMR (500 MHz, CDCl₃) δ 7.69 (s, 1H), 7.64 (d, *J* = 7.7 Hz, 1H), 7.47 (d, *J* = 7.8 Hz, 1H), 7.36 (t, *J* = 7.9 Hz, 1H), 4.50 (dtd, *J* = 13.3, 10.7, 2.7 Hz, 1H), 3.66 (ddd, *J* = 10.0, 5.8, 3.9 Hz, 1H), 3.58 (td, *J* = 10.3, 4.7 Hz, 1H), 2.47 (dddd, *J* = 15.7, 10.4, 5.8, 2.7 Hz, 1H), 2.34 (ddq, *J* = 15.1, 11.0, 3.9 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 136.12 (t, *J* = 26.6 Hz), 133.78, 130.08, 129.11 (t, *J* = 6.4 Hz), 124.66 (t, *J* = 6.1 Hz), 122.59, 119.15 (t, *J* = 249.8, 247.7 Hz), 53.80 – 50.59 (m), 34.37 (t, *J* = 2.6 Hz), 30.26.


¹⁹F NMR (471 MHz, $c_{6}d_{6}$) δ -97.98 (dd, J = 246.8, 10.3 Hz), -101.04 (dd, J = 246.5, 13.3 Hz).

HRMS (EI): for $C_{10}H_9Br_3F_2$, [M]⁺ calculated m/z = 403.8217 and 405.8196 and 407.8176 and 409.8156, found m/z = 403.8211 and 405.8190 and 407.8169 and 409.8149.





Derivatizations




5. (S)-1-(2-azido-1,1-difluoropropyl)-3-nitrobenzene. To a solution of **1a** (28 mg, 0.1 mmol) in DMSO (0.3 mL) under N_2 , was added solid NaN₃ (20 mg, 3 equiv). The mixture was briefly degassed by direct exposure to high vacuum, refilled with N_2 , and sealed. The mixture was heated at 100°C for 12 hours, and upon cooling was diluted with brine. The aqueous layer was extracted 3x with Et₂O, and the combined organic layers were washed 3x with brine, dried over MgSO₄, filtered, and concentrated. The crude residue was purified by column chromatography eluting with Hexanes/Et₂O on a gradient from pure hexanes to 5% Et₂O, affording the title compound as a colorless oil (18 mg, 74%).


¹H NMR (500 MHz, CDCl₃) δ 8.40 – 8.33 (m, 1H), 7.88 – 7.82 (m, 0H), 7.68 (t, *J* = 7.9 Hz, 0H), 3.99 – 3.87 (m, 0H), 1.38 (d, *J* = 6.8 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 148.19, 135.86 (t, *J* = 27.3 Hz), 131.96 (t, *J* = 6.0 Hz), 129.74, 125.34, 121.37 (t, *J* = 6.8 Hz), 120.22 (d, *J* = 249.7 Hz), 60.91 (t, *J* = 30.8 Hz), 13.06 (t, *J* = 3.2 Hz).


¹⁹F NMR (471 MHz, CDCl₃) δ -101.13 (dd, J = 252.3, 7.8 Hz, 1F), -108.82 (dd, J = 252.5, 12.7 Hz, 1F). HRMS (ESI): for C₉H₈F₂O₂Na, [M+Na]⁺ calculated *m/z* = 265.0508, found *m/z* = 265.0508.

Chiral GC: CP-Chirasil-Dex CB, isothermal 110 °C, 14 psi, 90% ee





-93 -94 -95 -96 -97 -98 -99 -100 -101 -102 -103 -104 -105 -106 -107 -108 -109 -110 -111 -112 -113 -114 -115 -116 -117 -118 -119 -120 f1 (ppm)




S2 (R)-S-(3-bromo-4-(3-bromophenyl)-4,4-difluorobutyl) ethanethioate. To a solution of **1t** (82 mg, 0.2 mmol) in DMSO (2 mL) under N_2 , was added solid KSAc (46 mg, 2 equiv). The mixture was briefly degassed by direct exposure to high vacuum, refilled with N_2 , and sealed. The mixture was stirred at room temperature for 1 hour, and upon cooling was diluted with brine. The aqueous layer was extracted 3x with Et₂O, and the combined organic layers were washed 3x with brine, dried over MgSO₄, filtered, and concentrated. The product was used without further purification (80 mg, 77%).


¹H NMR (500 MHz, Chloroform-*d*) δ 7.64 (s, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.43 (d, *J* = 7.9 Hz, 1H), 7.31 (t, *J* = 7.9 Hz, 1H), 4.28 (td, *J* = 13.3, 12.0, 9.2 Hz, 1H), 3.21 (ddd, *J* = 13.0, 7.8, 4.4 Hz, 1H), 2.92 (dt, *J* = 13.9, 8.0 Hz, 1H), 2.32 (s, 3H), 2.23 (dtd, *J* = 15.7, 8.9, 7.9, 2.4 Hz, 1H), 2.05 (dddd, *J* = 15.2, 11.7, 7.7, 4.4 Hz, 1H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 194.99, 136.13 (t, J = 26.9 Hz), 133.68, 129.99, 129.17 (t, J = 6.4 Hz), 124.77 (t, J = 6.2 Hz), 122.50, 119.17 (t, J = 248.4 Hz), 53.19 (t, J = 31.9 Hz), 31.72 (t, J = 2.4 Hz), 30.66, 26.97. ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -97.39 (dd, J = 246.7, 10.0 Hz, 1F), -100.81 (dd, J = 246.5, 12.7 Hz, 1F). HRMS (EI): for C₁₂H₁₂Br₂F₂OS, [M]⁺ calculated m/z = 399.8938 and 401.8918 and 403.8897, found m/z = 399.8937 and 401.8915 and 403.8893.

Chiral HPLC: Chiralcel OD-H, 1.0% isopropanol/hexanes, 1.0 ml/min, 76% ee




Signal 3: DAD1 C, Sig=230,4 Ref=450,100




Signal 3: DAD1 C, Sig=230,4 Ref=450,100

Peak H	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	90
-						
1	8.525	VV	0.2268	676.37372	45.67154	12.0967
2	9.176	VB	0.2478	4915.01953	305.29327	87.9033



S3. (R)-3-bromo-4-(3-bromophenyl)-4,4-difluorobutane-1-thiol. To a solution of **S2** (159 mg, 0.39 mmol) in methanol (8 mL) under N₂, was added solid K₂CO₃ (110 mg, 2 equiv). The mixture was briefly degassed by direct exposure to high vacuum, refilled with N₂, and sealed. The mixture was stirred at room temperature for 1 hour and quenched with aqueous ammonium chloride. The aqueous layer was extracted 3x with Et₂O, and the combined organics dried over MgSO₄, filtered, and concentrated. The residue was purified by column chromatography on SiO₂ eluting with Hexanes/Et₂O as a clear, colorless oil. (104 mg, 73%).


¹H NMR (500 MHz, Chloroform-*d*) δ 7.67 (t, J = 1.9 Hz, 1H), 7.61 (dd, J = 7.9, 2.0 Hz, 1H), 7.46 (dd, J = 7.9, 1.6 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 4.56 – 4.45 (m, 1H), 2.87 (dtd, J = 13.7, 7.1, 4.4 Hz, 1H), 2.65 (dtd, J = 13.6, 9.1, 6.8 Hz, 1H), 2.13 (tdd, J = 9.4, 7.4, 4.5 Hz, 2H), 1.35 (dd, J = 9.3, 7.7 Hz, 1H). ¹³C NMR (126 MHz, Chloroform-*d*) δ 136.33 (t, J = 26.8 Hz), 133.69, 130.04, 129.15 (t, J = 6.5 Hz), 124.72 (t, J = 6.1 Hz), 122.55, 119.31 (t, J = 247.9 Hz), 52.87 (t, J = 31.5 Hz), 35.21 (d, J = 2.3 Hz), 22.36. ¹⁹F NMR (471 MHz, Chloroform-*d*) δ -97.99 (dd, J = 246.3, 10.7 Hz, 1F), -100.21 (dd, J = 246.3, 13.0 Hz, 1F). HRMS (EI): for C₁₀H₁₀Br₂F₂S, [M]⁺ calculated *m*/*z* = 357.8833 and 359.8812 and 361.8792, found *m*/*z* = 357.8835 and 359.8813 and 361.8792.





7. (S)-2-((3-bromophenyl)difluoromethyl)thietane. A solution of **S3** (53 mg, 0.147 mmol) in DMF (1.5 mL) was added under N₂ to solid NaH (95%, 4.2 mg, 1.2 equiv) [Caution! Sodium hydride in DMF can lead to runaway exothermic reactions on large scale.]. The mixture was briefly degassed by direct exposure to high vacuum, refilled with N₂, and sealed. The mixture was stirred at room 90 °C for 9 hours, and upon cooling to room temperature was quenched with aqueous ammonium chloride. The aqueous layer was extracted 3x with Et₂O, and the combined organics were washed three times with brine, dried over MgSO₄, filtered, and concentrated. The residue was purified by column chromatography on SiO₂ eluting with Hexanes/Et₂O as a clear, colorless oil (28 mg, 68%).

¹H NMR (500 MHz, Chloroform-*d*) δ 7.66 (t, *J* = 1.9 Hz, 1H), 7.61 – 7.52 (m, 1H), 7.45 (dt, *J* = 7.7, 1.3 Hz, 1H), 7.30 (t, *J* = 7.9 Hz, 1H), 3.97 (ddd, *J* = 15.4, 11.1, 7.7, 6.6 Hz, 1H), 3.14 – 3.02 (m, 2H), 3.02 – 2.94 (m, 2H). ¹³C NMR (126 MHz, Chloroform-*d*) δ 136.61 (t, *J* = 27.5 Hz), 133.30, 129.99, 128.87 (t, *J* = 6.2 Hz), 124.36 (t, *J* = 5.9 Hz), 120.84 (t, *J* = 208.4 Hz), 44.04 (t, *J* = 31.1 Hz), 26.40 (t, *J* = 3.5 Hz), 21.33.

¹⁹F NMR (471 MHz, Chloroform-*d*) δ -105.44 (dd, J = 244.1, 11.1 Hz, 1F), -108.25 (dd, J = 244.1, 15.5 Hz, 1F). HRMS (EI): for C₁₀H₉BrF₂S, [M]⁺ calculated m/z = 277.9571 and 279.9550, found m/z = 277.9568 and 279.9545. Chiral GC: β-Cyclosil, isothermal 120 °C, 14 psi, 76% ee










6. (S)-2-(difluoro(4-nitrophenyl)methyl)oxirane. A solution of **1s** (29.6 mg, 0.1 mmol) in THF (0.8 mL) was added under N₂ to a suspension of NaH (95%, 4.8 mg, 2 equiv) in THF (0.2 mL) at room temperature. The mixture was stirred for 15 minutes and was quenched by aqueous ammonium chloride. The aqueous layer was extracted 3x with Et₂O, and the combined organics dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on SiO₂ eluting with Hexanes/Et₂O and isolated as a white solid (13 mg, 70%).

¹H NMR (500 MHz, CDCl₃) δ 8.30 (d, J = 8.2 Hz, 2H), 7.76 – 7.63 (m, 2H), 3.46 (dddd, J = 9.2, 5.4, 3.9, 2.4 Hz, 1H), 2.90 (ddd, J = 5.3, 3.6, 1.6 Hz, 1H), 2.79 (dd, J = 5.0, 2.3 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 149.28, 139.69 (t, J = 26.8 Hz), 127.06, 123.69, 118.05 (dd, J = 246.1, 243.3 Hz), 52.24 (dd, J = 40.6, 36.8 Hz), 43.68. ¹⁹F NMR (471 MHz, CDCl₃) δ -102.81 (d, J = 263.8 Hz, 1F), -107.72 (dd, J = 263.7, 2.3 Hz, 1F). HRMS (EI): for C₉H₇F₂NO₃, [M]⁺ calculated m/z = 215.0389, found m/z = 215.038. Chiral GC: β-Cyclosil, 40 °C to 120 °C, 1 °C/min, 14 psi, 92% ee





X-ray Crystallography: X-ray crystallography quality crystals were obtained of the following derivative (prepared by azide displacement using the method described for 5 on 1i followed by the standard click-chemistry technique with p-bromophenylacetylene) by vapor diffusion of pentane into MTBE:



S4. (S)-4-(4-bromophenyl)-1-(1,1-difluoro-1-(4-nitrophenyl)butan-2-yl)-1H-1,2,3-triazole. The azide product (3 mg, 0.012 mmol, 1 equiv) was dissolved in a 1:1 mixture of *t*BuOH/H₂O (0.05M overall). To this solution was added, in succession, p-bromophenylacetylene (2.5 mg, 0.014 mmol, 1.2 equiv), CuSO₄•5H₂O (0.8 mg, 0.003 mmol, 0.25 equiv), and sodium ascorbate (1.2 mg, 0.006 mmol, 0.5 equiv). The vial was placed under an N₂ atmosphere and sealed with electrical tape. The solution was stirred overnight at room temperature. After this time, the reaction mixture was diluted with EtOAc and H₂O. The organic layers were separated and washed with brine, dried over MgSO₄, filtered, and concentrated by rotary evaporation. The crude material was then purified by flash column chromatography (5% to 60% Et₂O/Hexanes) to afford **S4** as a white solid (5 mg, 95% yield).

X-ray crystallography: A crystal mounted on a diffractometer was collected data at 100 K. The intensities of the reflections were collected by means of a Bruker APEX II CCD diffractometer ($Mo_{K\alpha}$ radiation, λ =0.71073 Å), and equipped with an Oxford Cryosystems nitrogen flow apparatus. The collection method involved 0.5° scans in ω at 28° in 2 θ . Data integration down to 0.78 Å resolution was carried out using SAINT V8.37A⁷ with reflection spot size optimization. Absorption corrections were made with the program SADABS.⁷ The structure was solved by the Intrinsic Phasing methods and refined by least-squares methods again F^2 using SHELXT-2014⁸ and SHELXL-2014⁹ with OLEX 2 interface.¹⁰ Non-hydrogen atoms were refined anisotropically, and hydrogen atoms were allowed to ride on the respective atoms. Crystal data as well as details of data collection and refinement are summarized in Table 1, and geometric parameters are shown in Table 2. The Ortep plots produced with SHELXL-2014 program, and the other drawings were produced with Accelrys DS Visualizer 2.0.¹¹

Tab	le	S1.	Expe	rimen	tal c	letai	S
-----	----	-----	------	-------	-------	-------	---

	MLII-99-2
Crystal data	
Chemical formula	$C_{18}H_{15}BrF_2N_4O_2$
M _r	437.25

Crystal system, space group	Monoclinic, P2 ₁
Temperature (K)	100
<i>a</i> , <i>b</i> , <i>c</i> (Å)	12.6771 (15), 5.6603 (7), 13.2825 (15)
β (°)	112.3222 (18)
$V(Å^3)$	881.68 (18)
Ζ	2
Radiation type	Μο Κα
μ (mm ⁻¹)	2.37
Crystal size (mm)	$0.10 \times 0.04 \times 0.02$
Data collection	
Diffractometer	Bruker D8 goniometer with CCD area detector
Absorption correction	Multi-scan SADABS
T_{\min}, T_{\max}	0.565, 0.746
No. of measured, independent and observed $[I > 2\sigma(I)]$ reflections	5582, 3654, 2999
R _{int}	0.030
$(\sin \theta / \lambda)_{max} (\text{Å}^{-1})$	0.641
Refinement	
$R[F^2 > 2\sigma(F^2)], wR(F^2), S$	0.051, 0.119, 1.03
No. of reflections	3654
No. of parameters	245
No. of restraints	1
H-atom treatment	H-atom parameters constrained
$\Delta \rho_{\text{max}}, \Delta \rho_{\text{min}} (e \text{ Å}^{-3})$	1.13, -0.38
Absolute structure	Flack x determined using 1028 quotients [(I+)-(I-)]/[(I+)+(I-)] (Parsons, Flack and Wagner, Acta Cryst. B69 (2013) 249-259).
Absolute structure parameter	-0.004 (13)

Computer programs: *SAINT* 8.37A (Bruker-AXS, 2015), *SHELXT2014* (Sheldrick, 2015), *SHELXL2014* (Sheldrick, 2015), Bruker *SHELXTL* (Sheldrick, 2015).

Table S2. Geometric parameters (Å, °)

D 1 01(1.000 (7)		1.510 (10)
Br1—C16	1.908 (7)	C7—C8	1.518 (10)
F1—C7	1.369 (9)	C8—C9	1.529 (10)
F2—C7	1.373 (8)	С8—Н8	1.0000
O1—N4	1.253 (9)	C9—C10	1.505 (10)
O2—N4	1.203 (10)	С9—Н9А	0.9900
N1—N2	1.320 (7)	С9—Н9В	0.9900
N1—C12	1.364 (9)	C10—H10A	0.9800
N2—N3	1.355 (8)	C10—H10B	0.9800
N3—C11	1.347 (8)	C10—H10C	0.9800
N3—C8	1.475 (8)	C11—C12	1.384 (9)
N4—C3	1.480 (8)	C11—H11	0.9500
C1—C6	1.384 (10)	C12—C13	1.473 (9)
C1—C2	1.403 (9)	C13—C14	1.393 (12)
C1—H1	0.9500	C13—C18	1.396 (9)
C2—C3	1.379 (10)	C14—C15	1.384 (9)
С2—Н2	0.9500	C14—H14	0.9500
C3—C4	1.381 (9)	C15—C16	1.374 (10)
C4—C5	1.379 (9)	C15—H15	0.9500
C4—H4	0.9500	C16—C17	1.371 (10)
C5—C6	1.403 (12)	C17—C18	1.387 (9)
С5—Н5	0.9500	С17—Н17	0.9500
С6—С7	1.524 (10)	C18—H18	0.9500
N2—N1—C12	108.9 (6)	С9—С8—Н8	107.9
N1—N2—N3	106.8 (6)	С10—С9—С8	113.9 (6)
C11—N3—N2	111.6 (5)	С10—С9—Н9А	108.8
C11—N3—C8	128.7 (6)	С8—С9—Н9А	108.8
N2—N3—C8	119.6 (5)	С10—С9—Н9В	108.8
O2—N4—O1	124.2 (6)	С8—С9—Н9В	108.8
O2—N4—C3	119.2 (7)	Н9А—С9—Н9В	107.7
O1—N4—C3	116.6 (8)	С9—С10—Н10А	109.5
C6—C1—C2	120.0 (6)	С9—С10—Н10В	109.5
С6—С1—Н1	120.0	H10A—C10—H10B	109.5
С2—С1—Н1	120.0	С9—С10—Н10С	109.5

	117 4 (6)		100.5
C3—C2—C1	117.4 (6)	H10A—C10—H10C	109.5
C3—C2—H2	121.3	H10B—C10—H10C	109.5
C1—C2—H2	121.3	N3—C11—C12	104.1 (6)
C2—C3—C4	123.5 (7)	N3—C11—H11	127.9
C2—C3—N4	119.2 (7)	C12—C11—H11	127.9
C4—C3—N4	117.3 (6)	N1—C12—C11	108.6 (6)
C5—C4—C3	119.0 (7)	N1—C12—C13	122.7 (6)
C5—C4—H4	120.5	C11—C12—C13	128.7 (6)
C3—C4—H4	120.5	C14—C13—C18	118.7 (6)
C4—C5—C6	119.1 (7)	C14—C13—C12	120.7 (6)
С4—С5—Н5	120.5	C18—C13—C12	120.7 (6)
С6—С5—Н5	120.5	C15—C14—C13	120.8 (7)
C1—C6—C5	121.0 (6)	С15—С14—Н14	119.6
C1—C6—C7	118.5 (6)	C13—C14—H14	119.6
C5—C6—C7	120.5 (6)	C16—C15—C14	119.1 (7)
F1—C7—F2	105.1 (5)	С16—С15—Н15	120.4
F1—C7—C8	109.8 (6)	С14—С15—Н15	120.4
F2—C7—C8	109.4 (5)	C17—C16—C15	121.6 (6)
F1—C7—C6	108.8 (5)	C17—C16—Br1	120.5 (6)
F2—C7—C6	109.5 (6)	C15—C16—Br1	118.0 (5)
C8—C7—C6	113.8 (6)	C16—C17—C18	119.4 (7)
N3—C8—C7	108.6 (6)	С16—С17—Н17	120.3
N3—C8—C9	110.9 (5)	С18—С17—Н17	120.3
С7—С8—С9	113.5 (6)	C17—C18—C13	120.4 (6)
N3—C8—H8	107.9	С17—С18—Н18	119.8
С7—С8—Н8	107.9	С13—С18—Н18	119.8
C12—N1—N2—N3	-0.3 (7)	F2—C7—C8—N3	-52.8 (7)
N1—N2—N3—C11	0.9 (7)	C6—C7—C8—N3	-175.7 (6)
N1—N2—N3—C8	179.4 (5)	F1—C7—C8—C9	-174.1 (5)
C6—C1—C2—C3	0.9 (10)	F2—C7—C8—C9	71.0 (7)
C1—C2—C3—C4	1.6 (10)	С6—С7—С8—С9	-51.9 (8)
C1—C2—C3—N4	-177.5 (6)	N3—C8—C9—C10	-59.4 (8)
O2—N4—C3—C2	169.8 (7)	C7—C8—C9—C10	177.9 (6)
L	1		1

		-	
O1—N4—C3—C2	-7.8 (9)	N2—N3—C11—C12	-1.1 (7)
O2—N4—C3—C4	-9.4 (9)	C8—N3—C11—C12	-179.4 (6)
O1—N4—C3—C4	172.9 (6)	N2—N1—C12—C11	-0.3 (7)
C2—C3—C4—C5	-2.4 (10)	N2—N1—C12—C13	-179.9 (6)
N4—C3—C4—C5	176.8 (6)	N3—C11—C12—N1	0.9 (7)
C3—C4—C5—C6	0.6 (10)	N3—C11—C12—C13	-179.6 (6)
C2—C1—C6—C5	-2.6 (10)	N1—C12—C13—C14	160.4 (6)
C2—C1—C6—C7	177.6 (6)	C11—C12—C13—C14	-19.1 (10)
C4—C5—C6—C1	1.9 (10)	N1—C12—C13—C18	-19.8 (10)
C4—C5—C6—C7	-178.3 (6)	C11—C12—C13—C18	160.7 (7)
C1—C6—C7—F1	52.7 (8)	C18—C13—C14—C15	1.7 (9)
C5—C6—C7—F1	-127.0 (7)	C12—C13—C14—C15	-178.5 (6)
C1—C6—C7—F2	167.2 (6)	C13—C14—C15—C16	-0.7 (10)
C5—C6—C7—F2	-12.6 (9)	C14—C15—C16—C17	-0.4 (10)
C1—C6—C7—C8	-70.0 (8)	C14—C15—C16—Br1	179.5 (5)
С5—С6—С7—С8	110.2 (7)	C15—C16—C17—C18	0.5 (10)
C11—N3—C8—C7	86.8 (8)	Br1-C16-C17-C18	-179.5 (5)
N2—N3—C8—C7	-91.4 (7)	C16—C17—C18—C13	0.6 (10)
C11—N3—C8—C9	-38.6 (10)	C14—C13—C18—C17	-1.7 (9)
N2—N3—C8—C9	143.3 (6)	C12—C13—C18—C17	178.5 (6)
F1—C7—C8—N3	62.1 (7)		




Figure S9. Perspective views showing 50% probability displacement




Figure S10. Three-dimensional supramolecular architecture viewed along the *b*-axis direction.

References:

- 1) Jobin-Des Lauriers, A.; Legault, C. Y. Iodine(III)-Mediated Oxidative Hydrolysis of Haloalkenes: Access to α-Halo Ketones by a Release-and-Catch Mechanism. *Org. Lett.* 2016, *18*, 108-111.
- Paraja, M.; Barroso, R.; Cabal, M. P.; Valdés, C. Synthesis of Highly Substituted Polyenes by Palladium-Catalyzed Cross–Couplings of Sterically Encumbered Alkenyl Bromides and N-Tosylhydrazones. *Adv. Synth. Catal.* 2017, 359, 1058-1062.
- Shunatona, H. P.; Fruh, N.; Wang, Y.-M.; Rauniyar, V.; Toste, F. D. Enantioselective Fluoroamination: 1,4-Addition to Conjugated Dienes Using Anionic Phase-Transfer Catalysis. *Angew. Chem. Int. Ed.* 2013, 52, 7724-7727.
- 4) Murphy, S. K.; Dong, V. M. Enantioselective Ketone Hydroacylation Using Noyori's Transfer Hydrogenation Catalyst. J. Am. Chem. Soc. 2013, 135, 5553-5556.
- 5) Banik, S. M.; Medley, J. W.; Jacobsen, E. N. Catalytic, asymmetric difluorination of alkenes to generate difluoromethylated stereocenters. *Science* **2016**, *353*, 51-54.
- 6) Commercial *m*CPBA (77% by weight) was found to give irreproducible results. Purified *m*CPBA was found to give consistent yields and selectivities. *m*CPBA was purified by the standard method: Schwartz, N. N., Blumbergs, J. H. Epoxidations with m-Chloroperbenzoic Acid. J. Org. Chem. 1964, 29, 1976-1979.
- 7) Bruker AXS APEX3, Bruker AXS, Madison, Wisconsin, 2016.
- 8) Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann H. OLEX2: a complete structure solution, refinement and analysis program. *J. Appl. Cryst.* **2009**, *42*, 339-34.
- 9) Sheldrick, G. M. SHELXT Integrated space-group and crystal-structure determination. *Acta Cryst.* 2015. A**71**, 3-8.
- 10) Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Cryst. 2015, C71, 3-8.
- 11) Accelrys DS Visualizer v2.0.1, Accelrys Software. Inc., 2007.